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Abstract 
Postantibiotic effect (PAE) is the persistent suppression of bacterial growth 
resulting from a previous exposure to an antimicrobial agent. Its important implications 
in the prolongation of the dosing interval for antimicrobials have been observed. And 
large numbers of studies have been conducted to investigate the PAE exhibited by a wide 
variety ofantimicrobials and organisms in an attempt to provide theoretical bases for the 
design of extended dosing regimens for antimicrobials. Despite intensive studies, the 
importance of different antimicrobial combinations on PAE has not been quantified. In 
view of this, our present project aims at characterizing the PAE exhibited by 
combinations of different antimicrobial agents. 
Although a series of methods investigated the inhibitory or bactericidal activities 
ofantimicrobial combinations have been established, a universal method for targeting the 
assessment of the PAE is not available. Therefore, the Fractional Maximal Effect method 
(FME method) has been verified in this thesis for the assessment o fPAE demonstrated by 
antimicrobial combinations. This method has been shown to be capable of determining 
both synergistic and antagonistic interactions on PAE. In addition，it enables the highest 
interactive concentration ratio for the test combinations to be determined. With the 
availability of this standardized method, the contribution of PAE with respect to the 
selection ofantimicrobial combinationsfor chemotherapy can be readily studied. 
Since PAE has mainly been studied under in vitro conditions, its significance in 
clinical environment should also be considered. Therefore, the effects produced by two 
clinical factors such as sequential dosing and antimicrobial resistance on the PAE 
induced by antimicrobial combinations were further investigated. 
In the clinical setting, antimicrobial combinations are usually administered 
sequentially as a result of the independent dosing schedules for each of the individual 
antimicrobials. The effects of such sequential administration of an antimicrobial 
combination on the PAE were investigated. Studies conducted on rifampin and 
tobramycin against E. coli ATCC 25922 demonstrated that both the order and interval of 
antimicrobial administration affected the PAE produced by the combination. Whenever 
this dosage combination is employed for chemotherapy，both of these aspects including 
the order and interval of drug administration should be considered carefully. In addition, 
the administration of an antimicrobial during the postantibiotic phase should be avoided 
as an antagonistic effect on PAE may occur. 
As PAE is an important factor in antimicrobial chemotherapy，the problem of 
antimicrobial resistance on PAE must also be considered. Studies on a typical synergistic 
combination, piperacillin and gentamicin against standard and resistant strains of Ps, 
aeruginosa showed that the effect of antimicrobial resistance on resulting PAE was 
specific to the resistance induced to the two individual antibiotics. A minor change (from 
0.5 MIC to 2 MIC) in gentamicin resistance caused a significant reduction in the 
synergistic PAE produced by this combination. On the other hand, piperacillin resistance 
did not pose any observable changes in the PAE exhibited by the combination. 
In the present studies, the impact of some clinical factors on the PAE produced by 
antimicrobial combinations has been determined. Some important aspects o fPAE on the 
design of dosing regimens for antimicrobial combination therapy have been 
demonstrated. How well the data obtained in the present studies reflect the actual clinical 
situations is a subject for further investigations. 
摘要 
後抑菌效應（Postantibiotic E f f e c t ) 是 細 菌 與 抗 生 素 接 觸 後 
所 產 生 的 一 種 持 續 抑 菌 作 用 ， 由 於 該 效 應 可 以 延 長 用 
药 間 隔 時 間 ， 所 以 引 起 大 量 有 關 研 究 。 現 時 有 關 這 方 
面 的 硏 究 集 中 於 單 一 抗 生 素 的 硏 究 ， 而 抗 生 素 配 伍 對 
後 抑 菌 效 應 的 影 嚮 仍 未 被 深 入 硏 究 。 爲 了 解 抗 生 素 配 
伍 對 後 抑 菌 效 應 的 影 徵 ， 本 論 文 採 用 兩 種 抗 生 素 聯 合 
用 药 對 後 抑 菌 效 應 作 一 較 深 入 硏 究 。 
本文採用並証實 F r a c t i o n a l Maximal Effect M e t h o d 是一種硏 
究 抗 生 素 組 合 後 產 生 的 後 抑 菌 效 應 的 有 效 手 段 ° 該 方 
法 能 檢 測 出 抗 生 素 組 合 後 對 後 抑 菌 效 應 的 協 同 與 不 協 
同 相 互 作 用 ， 而 且 利 用 這 方 法 能 確 切 地 找 出 兩 種 抗 生 
素 之 間 對 後 抑 菌 效 應 的 最 大 相 互 作 用 濃 度 比 ° 本 硏 究 
結 果 將 能 把 後 抑 菌 效 應 的 硏 究 帶 入 抗 生 素 組 合 的 領 域 
中 ， 從 而 爲 抗 生 素 組 合 化 療 提 供 合 理 用 窮 依 據 以 助 制 
訂 最 佳 的 治 療 方 案 。 
因 爲 在 臨 床 上 抗 生 素 組 合 所 產 生 的 後 抑 菌 效 應 對 
韵 物 配 伍 後 的 治 療 效 果 有 重 要 的 意 義 ， 本 硏 究 將 兩 個 
影 徵 臨 床 用 藉 效 果 的 因 素 即 用 韵 方 案 和 耐 药 性 對 抗 生 
素 組 合 所 帶 來 的 後 抑 菌 效 應 的 作 用 作 一 詳 細 兮 析 。 結 
果 表 明 以 上 兩 個 臨 床 因 素 對 抗 生 素 組 合 所 產 生 出 來 的 
後 抑 菌 效 應 有 明 顯 的 影 徵 ， 該 影 嚮 對 抗 生 素 組 合 化 療 
的 治 療 方 案 制 訂 有 重 大 意 義 ， 但 要 進 一 步 確 證 後 抑 菌 
效 應 對 臨 床 用 韵 的 實 際 意 義 ， 仍 需 作 更 深 入 的 硏 究 。 
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Background on Postantibiotic Effect 
Postantibiotic effect (PAE) is the persistent suppression of bacterial 
growth that follows a brief exposure to an antimicrobial agent (McDonald et al.， 
1977). It was first observed by Bigger in 1944 (Bigger, 1944). In his study, he 
noted a delay in development of turbidity in the cultures of staphylococci and 
streptococci previously exposed to penicillin G. Several years later, Parker & 
. Marsh (Parker and Marsh, 1946) and Parker & Luse (Parker and Luse, 1948) 
demonstrated that staphylococci after exposure to penicillin G for 5 to 30 
minutes did not resume normal growth for approximately 1 to 3 hours after 
being transferred to drug-free medium. Since these early discoveries of the 
persistent inhibitory effect ofpenicillin on gram-positive cocci, intensive studies 
in this area have extended this finding to Gram-negative bacilli and 
antimicrobials other than penicillins. As suggested by these studies, PAE 
appears to be a feature of virtually all antimicrobials against a variety of 
bacterial pathogens (Eagle and Musselman，1949; Bergan et al., 1980; Bundtzen 
et al., 1981; Gerber and Craig, 1981; Zhanel et al., 1991). Its presence and ^ 
duration depend on the types of organism and antimicrobial, the antibiotic 
concentrations employed and the duration of exposure (Zhanel et al., 1991). 
All antimicrobials, including beta-lactams, fluoroquinolones, amino-
glycosides, tetracyclines, rifampin, macrolides, trimethroprim, etc., induce PAE 
against Gram-positive cocci. In contrast, with respect to Gram-negative bacilli, 
not all antibiotic classes demonstrate PAEs. Among the different classes of 
antibiotics, aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol 
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and rifampin induce a long PAE, whereas beta-lactams demonstrate minimal or 
negative PAE, i.e. the cultures exposed to beta-lactams show a regrowth faster 
than the control culture. This observation for Gram-negative organisms may be a 
result of the formation of filamentous forms. This bacterial form induced by 
beta-lactam exposure divides faster than the control organism soon after drug 
removal. Unique among the beta-lactams, penems (e.g. imipenem) produces a 
significant PAE against most strains of Pseiidomonas aeruginosa. 
Several studies have shown that, in addition to the types of antimicrobial 
and organism, the concentration of the antibiotic and its duration of exposure 
also affect PAE (Eagle and Mussesman, 1949; McDonald et al., 1977; Wilson 
and Rolinson, 1979; Bundtzen et al., 1981). Increase in the concentration o f the 
antimicrobial prolongs PAE nonlinearly up to a maximal response. Beyond this, 
no further increase in PAE can be obtained by increasing antibiotic 
concentration. Coincidentally, the duration of antimicrobial exposure prolongs 
PAE in a similar fashion. In general, the prolongation in PAE resulting from a 
doubling of the exposure time is similar to that following a doubling of the 
concentration of antimicrobial. Therefore, both factors appear to have equal 
influence on PAE. Moreover, a distinct nonlinear relationship between the area 
under the drug concentration curve (AUC or concentration x exposure time) and 
the duration ofPAE was illustrated by Bundtzen et al. (Bundtzen et al., 1981). 
Importance ofPAE 
PAE has been demonstrated both in in vitro and in vivo studies. In 
addition to just being an in vitro phenomenon, PAE has shown some clinical 
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significance. By permitting the serum and tissue antibiotic levels to fall below 
the MIC without a significant degree of bacterial regrowth for a considerable 
period of time, PAE enables the dosing interval for the antimicrobial to be 
prolonged. Several animal studies (Gerber et al., 1983; Leggett et al., 1989; 
Vogelman et al., 1988) and limited human data (Sturm, 1989; Tulkens et al.， 
1988) have shown that antimicrobials exhibiting a long PAE can be 
administered over a longer dosing interval without much loss in efficacy. It is 
generally believed that the dosing interval for antimicrobials that induce a long 
PAE can be extended by an interval equal to its PAE. Conversely, the dosing 
regimen for antimicrobials that lack a significant PAE should require the serum 
and tissue drug concentrations to be maintained at or above the MIC for the 
entire dosing interval. 
By extending the dosing interval and thus allowing less frequent dosing, 
PAE shows a potential impact on reducing the cost and toxicity of certain 
antimicrobial chemotherapies. In an attempt to provide a theoretical basis for a 
better design ofdosing interval, a large number ofPAE studies on a wide variety 
of antimicrobials and organisms has been carried out. Despite intensive studies, 
the importance of antimicrobial combinations on PAE has not been realized. In 
view of this, the present project aims at studying the PAE exhibited by 
antimicrobial combinations. 
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The need for a method to study the interactions exhibited by antimicrobial 
combinations on PAE 
Most investigators engaging in antimicrobial combination research have 
demonstrated that when antimicrobial agents are combined, they may interact in 
a synergistic, additive or antagonistic manner. In order to determine the type of 
interaction between antimicrobials, a reliable assessment method is vital. 
Before the wide spread of interest on PAE studies, antimicrobial effects 
are mainly described in terms of inhibitory (e.g. minimum inhibitory 
concentration (MIC)) and bactericidal (e.g. minimum bactericidal concentration 
(MBC)) activities. For example, MIC is generally accepted to be the criterion for 
predicting the pharmacological response of an organism to the antimicrobial 
activity of the antibiotic. An organism is considered to be sensitive to an 
antimicrobial i f the concentrations of the antimicrobial achievable in serum after 
dosing are in excess of the MIC for that organism. Previous antimicrobial 
interaction studies have focussed on these inhibitory or bactericidal activities 
and no method is currently available for assessing the interaction of 
antimicrobials on PAE. To enable the interaction of antimicrobials on PAE to be 
determined, one of the major objectives of our study is to validate an assessment 
method for studying the PAE exhibited by antimicrobial combinations. 
Limitations ofthe current antimicrobial interaction assessment methods 
Although methods for assessing interactions between antimicrobials on 
PAE have not been established, currently available methods on studying 
antibiotic combination have to be reviewed for their capabilities. With reference 
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to these current methods for assessing interactions, several problems were 
observed. 
Standard method 
Currently, several methods are widely used for studying interactions 
based on inhibitory and bactericidal end points. However, a standard method has 
not been proposed. The checkerboard method and killing curve method are 
frequently employed in these studies. This checkerboard method assesses the 
inhibitory effect demonstrated by antimicrobials using lack of visible growth as 
an index for inhibitory activity, while the killing curve method utilizes the rate 
and the extent ofbacterial killing as an index for antimicrobial activity. Because 
two different microbial responses are employed by the two methods, generation 
ofpoorly correlated results is frequent (sometimes contradictory results). 
Standard criteriafor result interpretation 
As with the checkerboard method, definitions for synergy (e.g. fractional 
inhibitory concentration index (FIC index) = 0.5) and additivity (e.g. FIC index 
=1) are widely adapted. However, the definition for antagonism varies among 
different studies, i.e., FIC index ranges from > 1 to > 4 have been employed by 
different research groups (Hamilton-Miller, 1985; Krogstad and Moellering, 
1986). Therefore, standard criteria for evaluation of results are lacking. With the 
killing curve method, the activity measured for the combination is compared to 
that of the most active single agent alone before a conclusion can be drawn. 
Synergism, additive and antagonism are defined as more than 2 log units higher, 
士 1 log higher/lower or more than 2 log units lower in bacterial counts at 24 
6 
hours for the combination in comparison with the most active single agent, 
respectively (Eliopoulos and Moellering, 1991). These methods thus rely only 
on arbitrary criteria for the assessment of antimicrobial interactions. 
In order to ensure the consistency of results generated from various 
studies, a standard method with well-defined criteria for the evaluation ofresults 
should be established. Based on the generally accepted qualitative definitions for 
antimicrobial interactions, additivity should be used as a reference for defining 
antimicrobial interaction. Activity of the antimicrobial combination higher or 
lower than that of additivity should be defined as synergism and antagonism, 
respectively. A precisely defined additivity is therefore crucial for interaction 
assessments. However, it is surprised to note that most in vitro tests designed for 
antimicrobial interaction studies do not provide the definition of additivity for 
data interpretation. 
Correct additivityfor result interpretation 
Instead of additivity, the killing curve method employs the extent of 
killing over a specified interval by the most active agent as the basis to define 
antimicrobial interactions. Based on this arbitrary criterion, synergy can hardly 
be distinguished from additive, since killing activity higher than the most active 
single agent may be due to either the additional activity of the second agent or 
synergistic activity of the combination. 
With the checkerboard method, based on the assumption o fa linear dose-
response relationship, the additivity line, i.e., the sum of the FICs equal to 1，is 
constructed on an isobologram and used as a basis for interaction evaluation. 
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However, i f the assumption of a linear dose-response relationship dose not hold, 
this basis of additivity become invalid. Indeed, it is well-known that most 
antimicrobials possess a nonlinear concentration-response relationship as 
demonstrated in many pharmacodynamic studies (Garret and Wright, 1967; 
Kitzis et al., 1979). 
In an attempt to provide a correct definition for additivity during the 
evaluation of results and at the same time to avoid the need for an assumption 
with regard to the concentration-response relationship, a precise additivity 
definition generated on the basis of the actual concentration-response curve is 
necessary. 
Precise concentration-response curvefor defining additivity 
The assessment of antimicrobial interaction by the killing curve method 
does not require a predictable relationship between the extent ofkilling and the 
concentration of antimicrobial. Therefore such concentration-response 
relationships has not previously been defined. In fact, whether there is a 
predictable relationship between bacterial killing and the concentrations of an 
antimicrobial is still in question. Theoretically，a concentration-response curve 
that follows a nonlinear relationship can easily be generated by regression 
analysis. However, the overall killing after 24 hour exposure to an antimicrobial 
(activity as measured by the killing curve method) is a combined effect of the 
initial killing and subsequent inhibition ofbacterial growth. As a result，a precise 
relationship between this combined effect and the concentration of the 
antimicrobial is difficult to define. As with the checkerboard method, the use of 
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an all-or-none response (growth or no growth) makes the generation of a graded 
concentration-response curve impossible. Therefore, similar to the killing curve 
method, precise additivity can not be defined on the basis of the concentration-
response curve. 
In addition to the problems involved in establishing well-defined 
standard criteria for result evaluation, problems concerning the selection of 
antimicrobial concentration for interaction studies or result interpretation also 
exist. This limitation is briefly described below. 
A complete picture on interaction between antimicrobials 
As illustrated by Hyatt et al. and Sanders et al. (Hyatt et al.，1995; 
Sanders et al., 1993), interactions between antimicrobials may vary with the 
concentration ratios of antimicrobials. Since the checkerboard method and 
killing curve method depend on limited and specific concentration ratios for 
interaction studies or the evaluation of results, it will be difficult to draw a 
conclusion for interactions exhibited by antimicrobial combinations. 
The checkerboard method depends on concentration ratios as fractions of 
the MICs of the tested antimicrobials for the interpretation of result (e.g. during 
the evaluation of results using the FIC index). The killing curve method limits 
the use of the test concentrations at achievable serum concentrations only. Since 
both of these methods are based on certain specific concentration ratios for 
interaction assessment, this may lead to bias or over-generalized results. For 
instance, combinations that show contradicting interactions at different 
concentration ratios may create problems during the interpretation of results. 
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Antagonism determined in certain specific concentration ratios by these in vitro 
tests may exclude the application of certain synergistic concentration ratios and 
vice versa. 
Limitations of the study of PAE for antimicrobial combinations 
Several investigators have studied PAEs for antimicrobial combinations. 
Most of these studies concentrated on either penicillins or vancomycins in 
combination with aminoglycosides against Gram-positive coccus, especially 
Enterococcvs faecalis (Fuursted, 1987, 1988，1989; Hessen et al.，1989; 
Winstanley, 1989; Isaksson, 1991c). Although the number of studies is very 
limited, problems similar to those discussed previously for in vitro interaction 
assessments can easily be identified. For certain studies，synergism in PAE has 
been defmed as the PAE induced by the antimicrobial combination being longer 
than the sum of the PAEs induced by individual antibiotics (Gudmundsson et al., 
1991； Isaksson et al., 1991a, 1991b, 1991c). Whereas for others, the extent of 
prolongation o fPAE by the combination was evaluated based on the comparison 
of the PAE produced by the combination to that of the individual agents 
(Fuursted, 1987，1988, 1989; Hessen et al.，1989; Winstanley, 1989; Drabu, 
1991; Buxbaum et al., 1996). Lack ofstandardized criteria for the assessment of 
antimicrobial interactions with respect to PAE was evident. In some studies, 
limited concentrations of the antimicrobials, either arbitrary or clinically 
achievable serum levels, were selected for interaction studies (Fuursted, 
1987,1988,1989; Winstanley, 1989; Drabu, 1991; Walsh, 1995). In order to 
avoid bias, antimicrobial concentrations over a wide range were used in certain 
10 
studies. Various combinations at multiples of the MICs were employed 
(Gudmundsson et al., 1991; Isaksson, 1991c; Buxbaum et al., 1996). However, 
this non-standardized approach for concentration selection may result in the use 
of the sub-MIC or supra-MIC concentrations. Result comparison is therefore 
difficult. 
To tackle the above problems, the Fractional Maximal Effect method 
(FME method) is considered to be the best available method for our present 
studies on PAE demonstrated by antimicrobial combination. 
Fractional Maximal Effect method (FME method) 
The Fractional Maximal Effect method (FME method) was developed by 
Li et al. in 1993 (Li et al., 1993) and is based on providing a logical approach for 
studying the pharmacodynamic effect for antimicrobial combinations in which 
individual antibiotics display a nonlinear dose-response relationship. Basically, 
the FME method based on the sigmoidal Emax modal: 
E = Emax.Cn/(EC:5on + Cn)…“(1) 
E is the effect, 
Emax is the maximal effect, 
C is the concentration, 
EC50 is the concentration that produces half of the maximal 
effect, 
n is the Hill's coefficient, 
to relate the effect and concentration. Actual data collected for individual 
antibiotics are analysed by nonlinear regression for generation of the 
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concentration-response curves. For each antibiotic, FME is calculated as 
E/Emax- By rearranging equation 1, FME, therefore, correlates to concentration 
by the following equation: 
E/Emax = C" / (EC50" + C^)…"(2). 
With the utilization ofthis relationship between FME and the concentration，the 
concentration and effect can be interpreted graphically on a common axis using 
the FME scale (Figure 1). This allows a simple two-dimensional diagram to be 
used to describe the effects and concentrations both individually and in 
combination. It also reduces the need for the complicated three-dimensional 
diagram for graphical presentation. The simplification of graphical presentation 
for data obtained from combination studies is one of the most important feature 
of the FME method for interaction studies. 
The FME method avoids using arbitrary or wrong criteria for the 
evaluation of interaction by utilizing the actual dose-response relationships for 
individual antimicrobials in the definition of additivity for the interpretation of 
results. PAEs produced by individual antimicrobials at different concentrations 
were determined experimentally. They were then plotted on graphs with PAE 
against concentrations of the antimicrobial. By using the sigmoidal Emax model, 
the data points were fitted into concentration response curves by nonlinear 
regression for the estimation ofEmax, EC50 and n. Based on the concentration-
response relationships of the individual antimicrobials, a theoretical additive 
response is calculated by summing up the responses produced by individual 
antimicrobials within the combinations. This additivity then acts as a reference 
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for evaluating the interaction for antimicrobial combinations. By comparing the 
experimentally determined effect (Ep) to the additive effect OEx), the type of the 
interaction can be determined, e.g. Ep > Ex; Ep < Ex and Ep 二 Ex represent 
synergism, antagonism and additivity, respectively. In addition, an interaction 
index (R) can also be employed for further assessment of the interaction of the 
combination. The index is calculated by dividing the anticipated additive effect 
by the experimentally measured effect (R 二 Ep/Ex). R < 1，when Ex > Ep, R 二 1, 
when Ex = Ep and R > 1, when Ex < Ep indicate synergism, additivity and. 
antagonism, respectively. 
ln order to obtain a complete picture regarding the interactions (which 
may vary with concentration ratios), and at the same time，to prevent over-
generalized result generated on the basis of limited concentration ratios, the 
FME method provides a logical approach for selecting a broad range of 
concentration ratios for interaction studies. By adapting the common practice as 
used in the checkerboard method to keep a constant response of the 
combinations studied, the FME method allows a series of combinations having a 
constant total FME (TFME) for interaction studies (TFME is equal to the sum of 
the FMEs ofindividual antimicrobials). For example, if TFME is kept at 1, the 
following combinations, e.g., 0.1 FMEA + 0.9 FMEB, 0.2 FMEA + 0.8 FMER, 
0.3 FMEA +0.7 FMEB, etc. would be tested. The corresponding concentrations 
for individual antibiotics of the above combinations can be back-calculated by 
using equation 2 and then combined for the actual interaction studies. For each 
antimicrobial combination, the interaction indexes (R) for all of the tested 
13 
I 
concentration ratios are calculated and plotted against the concentration ratios of 
the antimicrobial combinations. As a result, a complete illustration of the 
interaction profile for the antimicrobial combination can be obtained. Any 
variation in the interaction along with the concentration ratios can easily be 
observed. Moreover the highest interactive combination，either synergistic or 
antagonistic，which is indicated by the smallest and the largest R values， 
respectively, can be determined from the graph directly. 
PAE studies for antimicrobial combinations using the Fractional Maximal 
Effect method (FME method) 
In our present studies, the FME method was used to study the PAEs 
produced by different antimicrobial combinations. Our intent is to investigate 
the validity of the FME method for studying the interactions exhibited by 
antimicrobial combinations on PAE. The success of this method with proper 
validation can provide a valuable tool for determining the PAEs or the 
interactions on PAE presented by antimicrobial combinations. This would be 
important for providing a rational basis to aid the selection of antimicrobials and 
the design ofdosage regimen for combination therapy. 
The efTect of non-simultaneous administration of antimicrobial 
combination on PAE 
Generally, antimicrobials showing a PAE allow its own serum levels 
falling below the MIC without significant bacterial regrowth for a period oft ime 
equal to the PAE. This enables the actual dosing interval for a PAE-inducing 
antimicrobial to be extended by an interval equal to its PAE. Using the same 
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theoretical basis, the dosing interval for a PAE-inducing antimicrobial 
combination could probably be extended by an interval equal to the PAE 
produced by that combination. In an attempt to aid the proper design of dosing 
interval for antimicrobial combinations, PAE studies on various antimicrobial 
combinations have been carried out. In most of these studies，PAEs induced by 
simultaneous exposure to the combinations were determined. This would be 
useful for the design of dosing regimen for antimicrobial combinations that are 
administered simultaneously. However, in common clinical settings, individual 
antimicrobials of the combination are administered with independent dosing 
schedules rather than administered simultaneously. Or for certain reasons, e.g. 
incompatibility ofpenicillin and aminoglycoside, penicillin and aminoglycoside 
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are successively administered rather than mixed together for simultaneous 
administration. In view of such practice, studies were conducted to investigate 
the effect of non-simultaneous administration of antimicrobial combination on 
the PAE. This set of experiments aims at providing informative data for the 
design ofsequential dosing for PAE-inducing antimicrobial combinations. 
When antimicrobial combinations are administered separately, they can 
be administered in different orders. Equally, the dosing between each 
antimicrobial can be separated by different time intervals. Thus, the effects 
exhibited by antimicrobial combination on the PAE with respect to the order and 
the dosing interval of antimicrobial administration were investigated in our 
studies. Furthermore, comparative studies on the PAEs obtained by sequential 
administration and that by simultaneous administration were conducted. These 
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studies were designed to show that PAE obtained by sequential dosing is either 
similar to or longer than that produced by simultaneous administration. 
Otherwise, the normal practice of non-simultaneous administration of 
antimicrobial combinations may need to be re-evaluated against simultaneous 
administration for further optimization of drug dosage in the clinical setting. 
The effect of antimicrobial resistance on the PAE exhibited by 
antimicrobial combinations 
As far as antimicrobial chemotherapy is concerned, the problem of 
bacterial resistance must be considered. Although successful development of 
potent antibiotics in this century has greatly contributed to the reduction of 
morbidity and mortality imposed by bacterial pathogens, the accelerating 
emergence of bacterial resistance produces serious problems threatening public 
health (Russel & Chopra, 1990; Levy, 1992; Neu，1992). Since the early 
discovery of penicillin, organisms have evolved efficient mechanisms of drug 
resistance rendering a number of valuable antimicrobials useless and now 
threaten the effectiveness of others (Neu, 1992; Alexander, 1994; Thornsberry, 
1995； Tenover & Mcgowan, 1996). To deal with this critical issue, measures 
intended to increase the bioavailability of the antimicrobial or to reduce the 
spread of resistant organism have been implemented. However, for the 
eradication of resistant strains and for achieving the ultimate solution to the 
resistance problem, new agents that are active against resistant pathogens must 
be invented. In the 1980's, there was little market potential for new 
antimicrobials because the older antibiotics were sufficient for the control of 
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infection disease, and consequently, most pharmaceutical companies shifted 
their research to more profitable therapeutic areas. As a result, new drugs for 
combating antimicrobial resistance become unavailable for quiet a long time. To 
cope with the fast emergence ofresistant pathogens, intensive studies among the 
currently available antimicrobial are now underway in an attempt to search for 
alternate single or combination antimicrobial therapies for the treatment of 
diseases caused by resistant pathogens. Understanding of the effects of 
antimicrobial resistance on PAE produced by antimicrobial combinations is 
important for the design of dosing regimens for combating these resistant 
organisms. Therefore, our present studies also aim at studying the effect of 
antimicrobial resistance on the PAE displayed by antimicrobial combinations. 
We believe that our studies will be helpful in aiding the search and design of 
alternate antimicrobial combination chemotherapy against resistant strains. 
Not until these fundamental issues listed previously are addressed can we 
be assured the use of antimicrobial is optimal. The author believes the work 
presented in this thesis will provide new insights into the optimal use of 
antibiotic combinations for chemotherapy. 
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Figure 1. The FME scale and the additivity line ofTFME = 1. 
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Chapter 2 
PAE studies for antimicrobial combination using the Fractional Maximal 
EfTect method (FME method) 
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Abstract 
The Fractional Maximal Effect method (FME method) recently developed 
for the study of antimicrobial combinations was selected to investigate the PAE 
exhibited by antimicrobial combinations. Using the FME method, the PAE 
produced by rifampin and tobramycin against E. coli ATCC 25922 was 
determined. In agreement with previous studies, a synergism on the PAE for this 
combination was demonstrated. This agreement supported the validity of the 
FME method to investigate the PAE for antimicrobial combinations. Studies on 
this synergistic combination as well as two other antagonistic combinations 
demonstrated the eligibility of the FME method in determining both interaction 
types, i.e., synergistic and antagonistic interaction, on PAE induced by 
antimicrobial combination. Moreover, the FME method enables the highest 
interactive concentration ratio for the combination to be determined. These data 




Antimicrobial combination therapy is frequently employed in different 
clinical situations. In general, it is employed (i) to provide broad spectrum 
coverage in empiric therapy for severe life-theatening infection pending 
identification of the causative agent, (ii) to treat documented or suspected 
polymicrobial infection when a single drug does not provide sufficient activity 
against all infecting pathogens, (iii) to prevent or minimize the emergence ofdrug 
resistant sub-populations, (iv) to reduce dose-related toxicities of antimicrobial 
when used as a single agent (Eliopoulos & Moellering, 1991). 
Antimicrobials when combined may interact in synergistic, additive or 
antagonistic manner against a given organism. To ensure a high rate of clinical 
success, synergistic combinations are chosen and antagonistic combinations are 
excluded. Currently, several in vitro tests for assessing the inhibitory and the 
bactericidal activities exhibited by antimicrobial combinations have been 
established. However, a single method for the assessment of antimicrobial 
interaction on PAE is not available. Therefore our present study aims at 
validating a method for determining the types of interaction on PAE. By 
providing a valid method for determining the PAE or the interaction onPAE for 
antimicrobial combinations, our studies may enable the rational design of dosing 
interval as well as the optimal selection of antimicrobials for combination therapy. 
With reference to currently available in vitro tests for antimicrobial 
combination testing (King et al., 1981; Eliopoulos & Moellering，1991), 
problems common to interaction studies are observed. At present, several 
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different methods are being employed for interaction assessment; however, a 
standard method has not been established. Among these methods, the 
checkerboard method and killing curve method are the most frequently used 
methods for interaction assessment. The checkerboard method is based on the 
assumption of a linear concentration-response relationship as the basis for the 
evaluation of interaction. The killing curve method employs the killing of the 
most active single agent as a reference for result interpretation. In fact，both 
methods rely on arbitrary criteria or assumptions for result evaluation, which in 
turn poses various problems for interaction assessment. Poor correlation of 
results produced among different methods is observed. Moreover, the 
dependence of certain specific concentration ratios for interaction assessment 
leads to over-generalization of results when defining the types of interaction 
between antimicrobials. 
Although studies on PAEs induced by antimicrobial combinations are 
very limited (Fuursted, 1987, 1988, 1989; Hessen et al., 1989; Winstanley & 
Hastings, 1989; Drabu & Blakemore, 1991; Gudmundsson et aL, 1991; Isaksson, 
et al., 1991a, 1991b, 1991c; Walsh, et al., 1995; Buxbaum & Georgopoulos, 
1996), problems similar to those previously discussed are identified. In many 
cases, both the PAE produced by individual agents and the sum of these PAEs 
are used as the basis for result interpretation. There is a lack of a standardized 
criterion for assessing the types ofinteraction on PAE. Although a wide range of 
antimicrobial concentration has been utilized in some studies in an attempt to 
provide a more complete interaction profile, the non-standardized strategy for 
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concentration selection resulting in the employment of sub-MIC and supra-MIC 
levels presents difficulties for comparison ofresults. 
Our present attempt is to verify the validity of the FME method for 
assessing the interactions ofantimicrobial on PAE. The FME method has recently 
been developed by Li et al. for antibiotic combination studies (Li et al., 1993). It 
is designed to provide a systematic approach for studying antibiotic combinations 
that produce nonlinear concentration-response relationships. With this method, 
the concentration-response curves for individual antimicrobials are generated 
experimentally. Using the sigmoidal Emax model for data fitting, the non-linear 
concentration-response relationships are produced for defining additivity for 
interaction assessment. This method (i) provides a well-defined standard 
interpretation criterion, (ii) avoids the use of arbitrary interpretation criteria, (iii) 
reduces the need for the assumption of a linear concentration-response 
relationship in interaction studies. 
In addition, to prevent the over-generalization of results generated on the 
basis of limited concentration ratios studied, the FME method provides a 
systematic approach for selecting concentration ratios with a broad-range for 
interaction studies. This enables the interaction profile exhibited by the 
antimicrobial combinations on PAE to be depicted. 
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Materials and Methods 
Aritimicrohial-organism combinations 
Thee antimicrobial-bacterium combinations were studied. M 
antimicrobials selected are known to produce PAE on the test bacteria. These 
combinations were selected to meet the intrinsic operational requirement of the 
FME method. Rifampin/tobramycin combination against Escherichia coli ATCC 
25922 which is known by a previous study to interact in a synergistic manner on 
PAE was chosen to investigate the validity of the FME method for studying the 
interaction on PAE. The interactions presented by two other combinations, 
tetracycline/ciprofloxacin against Escherichia coli ATCC 25922 and 
gentamicirVciprofloxacin against Pseiidomorias aeruginosa ATCC 27853 were 
also studied using the FME method. All antimicrobials were purchased from 
Sigma Chemical Co., St. Louis and the tested organisms were purchased from 
Difco Laboratories, Detroit Michigan. 
Culture media 
Mueller Hinton broth and nutrient agar purchased from Difco 
Laboratories, Detroit Michigan were used. Mueller Hinton broth was 
supplemented with 12.5^i g/ml o f M g � + and 25 i^gATil of Ca:+ according to the 
recommendation from National Committee for Clinical Laboratory Standards. 
Both media were sterilized by autoclaving as recommended by the manufacturer. 
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Preparation of Organisms 
The organisms were isolated and then subcultured on agar slants. One 
colony following isolation was saved on slants and was kept at 4 °C before the 
experiments. 
On the day before each experiment, bacteria on agar slant were 
transferred to broth and allowed to grow overnight at 37 T . On the day of the 
experiment, the overnight culture was diluted with fresh pre-warmed broth by 
1000-fold and then incubated at 3 7 � C for 2-2.5 h. This allowed the bacteria to 
q 
reach the logarithmic-growth phase and to attain an inoculum o f � 1 0 cfu/ml for 
initiation of the experiments. 
Antimicrobials 
Antimicrobial stock solutions at concentrations ten times that required for 
each experiment were prepared according to the recommendations from the 
manufacturer. They were stored at - 8 0 � C before use. MICs were determined by 
standard macrodilution method with reference to the recommendation proposed 
byNCCLS(NCCLS, 1993). 
Determination of postantibiotic effect. 
PAE was determined by colony counting method. This assay was used to 
follow the growth kinetics of the bacteria post antimicrobial exposure for PAE 
determination. 
To start the PAE experiment, the logarithmic-growth phase bacteria were 
exposed to antimicrobials either alone or in combination for one hour at 37 °C. 
One ml ofbacteria in the logarithmic-growth phase (-10^ cfu/ml) was added to 
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the antimicrobial containing medium (prepared by mixing 8 ml ofbroth with 1 ml 
of antimicrobial stock solution or 0.5 ml of each antimicrobial for combination 
studies) to generate an initial inoculum of � l o 6 cfu/ml. After one hour of 
incubation, the antimicrobial was removed by centrifugation at 2500 rpm for 10 
minutes and 3x washing with sterile 0.9% NaCl solution. The pellet was 
reconstituted with pre-warmed broth and incubated at 37 °C. Bacterial counts 
were followed by sampling at the start of the experiment, prior to and 
immediately after drug removal and every hour thereafter until enough data were 
collected to allow PAE determination. Viable counts were determined by 
microdilution method after placing samples on agar following serial ten-fold 
dilutions. Results were recorded after 18 hours ofincubation at 3 7 � C and plotted 
as Log viable counts (cfu/ml) against time. PAE was calculated according to the 
equation: PAE 二 T-C，where T is the time (in h) required for the viable count in 
the test culture to increase by one log!() unit above the count observed 
immediately after drug removal and C is the time required for the viable count in 
the antibiotic-free control culture to increase by one log!�unit above the count 
observed immediately after subjecting to identical drug removal procedures. 
The use ofthe control ensures that any delay in regrowth observed for the 
test cultures caused by factors other than antimicrobial exposure (e.g. mechanical 
disturbance, temporary deprivation of nutrients and abrupt temperature changes 




The FME method is divided into two parts. In the first part, 
concentration-response curves for individual antimicrobials against the test 
bacteria were defined by experiments. PAEs produced by a series of five test 
concentrations (e.g. 1 MIC, 2 MIC, etc.) were determined. Generally, 1 MIC was 
tested first to see whether subsequent studies should be extended to sub-MIC, 
supra-MIC concentrations or both, depending on the PAE and the extent o f the 
bactericidal activity produced by the drug. (e.g. high concentrations of strong 
bactericidal drugs may produce low or no viable counts for PAE determination. 
On the other hand, low concentrations of weak PAE-inducing antibiotics may 
yield very short PAEs and make accurate measurements very difficult). Data 
generated were then plotted with PAE on the Y-axis and antibiotic 
concentrations on the X-axis. The sigmoidal Emax pharmacodynamic model [E = 
Emax . C"/(EC50^ + C^)] was applied to the data by nonlinear regression 
(PCNONLIN, version 3.0’ SCI Software, Lexington, Ky). The parameters, 
Emax, EC50, n were estimated when the best-fit concentration-response curves 
were generated. 
In the second part o f the FME method, the PAEs of the combinations at 
different concentration ratios were measured. Antimicrobial combinations that 
gave a TFME (TFME =卩應八 + FMEg) equal to 1 were tested. The 
combinations selected were 0.2 FME^ + 0.8 FME^, 0.4 FME^ + 0.6 FMEg, 0.5 
FME^ + 0.5 FMEg, 0.6 FME^ + 0.4 FME^ and 0.8 FME^ + 0.2 FMEg (where A 
and B represent the two antimicrobials being studied). The concentrations of 
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individual antimicrobials for the above combinations were back calculated from 
the pre-defined concentration-response curves generated in the first part [e.g. 
based on the following rearrangement of the concentration-response equation: 
E/Emax 二 C" / (EC50" + C^) where E/Emax = FME]. By combining the 
corresponding concentrations for PAE determination, the experimental PAEs 
(PAEx) were measured. The expected PAEs (PAEp) for the additive 
combinations were calculated as the sum of the PAEs interpolated from the two 
concentration-response curves describing the combination. Any deviation of 
PAEx from PAEp was represented by the interaction index (R), i.e., PAEp/PAEx 
(R 二 1; additive, R > 1; antagonism, R < 1； synergism). For each antimicrobial 
combination being studied, the R values generated from the five antibiotic pairs 
were plotted against the concentration ratios of the two antimicrobials. The 
interaction profile for the combination was thereby produced. 
To present these data using the isobologram, an apparent TFME line was 
constructed by plotting R ‘ FME,, against FME^. The more potent antimicrobial 
with a higher Emax and/or lower EC50 is customarily plotted on the X-axis. 
With reference to the additivity line of TFME = 1, i.e., the line connecting the 
coordinates (0,1) and (1,0)，a concave apparent TFME indicates synergism while 
a convex TFME indicates antagonism. 
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Results 
The MICs measured for the test antibiotic-bacterium combinations are 
shown in Table I. The MICs of rifampin, tobramycin, ciprofloxacin and 
tetracycline against E, coli ATCC 25922 were 16 ^ig/ml, 2 ^ig/ml, 0.025 ^ig/ml 
and 2 pig/ml, respectively. Those of ciprofloxacin and gentamicin against Ps. 
aeruginosa ATCC 27853 were 1 |^ Lg/ml and 4 ^ig/ml, respectively. 
The growth kinetics of E. coli and Ps. aeruginosa after one hour of 
exposure to increasing concentrations of rifampin, tobramycin, tetracycline, 
ciprofloxacin (for E. coli\ gentamicin and ciprofloxacin (for Ps aeruginosa) are 
shown in Figures 1-6 (For raw data, please refer to Appendix I). As an 
illustration for the regrowth kinetics. Figure 1 shows that E. coli ATCC 25922 
after one hour of exposure to different concentrations of rifampin (1 MIC to 16 
MIC ) resulted in a stationary growth period before returning to normal growth. 
This lag-period of bacterial regrowth resulted from proceeding exposure to 
antimicrobial was known as PAE. As shown in Figure 1, PAE increased with 
higher concentrations of rifampin. 
Based on these regrowth patterns, PAEs were estimated and plotted on 
graphs to generate the concentration-response curves as shown in Figures 7-12 
(Actual data for the concentration response curves are given in Appendix II). All 
of the concentration-response curves were non-linear and the PAEs were 
saturable at high concentrations of the test antimicrobials. The increase in 
antimicrobial concentration was associated with the prolongation o fPAE up to a 
maximal PAE. The estimated Emax, EC50 and n values describing the best-fit 
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curves are shown in Table II. Among the antimicrobials tested against E. coli 
ATCC 25922, rifampin was the most effective PAE-producing antimicrobial with 
a Emax of4.78 h. In contrast, ciprofloxacin was the least effective PAE-inducing 
antimicrobial with a Emax of 1.05 h. Against Ps. aeruginosa ATCC 27853, 
ciprofloxacin and gentamicin produced a Emax of 3.89 h and 4.28 h, 
respectively. Gentamicin was slightly more effective than ciprofloxacin in 
producing PAE. In comparion the potencies of these PAE-producing drugs, 
ciprofloxacin and tobramycin showed the lowest E C 5 0 (0.80 and 0.86， 
respectively) and were considered to be more potent in producing PAE against E. 
coli ATCC 25922. Whereas tetracycline, with the highest EC50, was the least 
potent antibiotic in producing PAE against this organism. In line with the Emax 
estimates, gentamicin also showed a slightly smaller EC50 than ciprofloxacin and 
was comparatively more potent in producing PAE against Ps. aeruginosa ATCC 
27853. 
The concentrations ofthe antimicrobial combinations at TFME equal to 1 
are listed in Table III. For example, 24.65 |ig/ml of rifampin and 1.71 ^ig/ml of 
tobramycin corresponded to 0.5 FME for the two antibiotics against E. coli 
ATCC 25922. Based on the regrowth kinetics shown in Figures 13-15 (Raw data 
are listed in Appendix III), PAEs for these combinations were determined and are 
illustrated in Table IV. The expected PAEs for a theoretical additive combination 
(PAEp) and the interaction indexes (R) determined by R 二 PAEp/PAEx are 
shown alongside with the experimentally determined PAE (PAEx) in Table IV. 
The direction ofchanges with the interaction index (R) exhibited by rifampin and 
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tobramycin in combination against E. coli ATCC 25922, i.e., R < 1 suggests a 
synergistic interaction. On the contrary, combinations of ciprofloxacin 
/tetracycline against E. coli ATCC 25922 and ciprofloxacirVgentamicin against 
Ps, aeruginosa ATCC 25922 showed R > 1. These combinations were, 
therefore, antagonistic in nature. Independent of the types of interaction on PAE, 
all combinations demonstrated the highest degree ofinteraction at FME^ = FMEg 
=0.5. The most synergistic combination for rifampin and tobramycin against E. 
coli ATCC 25922 yielded the longest PAE of 5.96 h. For the combination of 
ciprofloxacin/tetracycline against E. coli ATCC 25922 and the combination of 
gentamicinv^ciprofloxacin against Ps. aeruginosa A T C C 27853， the strongest 
antagonistic combination produced the shortest PAE of 1.24 h and 2.74 h, 
respectively. 
The FME plots constructed by plotting R • FME^ against FME^ are 
shown in Figures 16-18. Results similar to that suggested by the interaction 
indexes were evident from these plots. The combination of rifampin and 
tobramycin against E. coli produced a concave FME plot (Figure. 16) suggesting 
a synergistic interaction on PAE. Whereas, a convex FME plot (Figure. 17) 
generated by the tetracycline and ciprofloxacin combination against E. coli 
indicated an antagonistic interaction. The combination of ciprofloxacin and 
gentamicin against Ps. aeruginosa produced a convex FME plot (Figure. 18) 
indicating an antagonistic interaction on PAE. 
The interaction profiles (R values against the concentration ratios of the 
antimicrobials) are shown in Figures 19-21. As shown in these figures, the R 
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values fluctuated with the concentration ratios. With reference to the data 
presented in Table I and the interaction profiles, the highest interactive 
concentration ratio for the combinations having the largest or the smallest R were 
determined. The most synergistic combination for rifampin plus tobramycin 
against E. coli was 25.65 pigMil of rifampin plus 1.71 ^ig/ml of tobramycin. For 
the combination of ciprofloxacin plus tetracycline against E. coli and that of 
ciprofloxacin plus gentamicin against Ps. aeruginosa, the most antagonistic 
combinations were 0.02 ^ig/ml of ciprofloxacin plus 8.01 ^ig/ml of tetracycline 
and 1.56 |ig/ml ofciprofloxacin plus 2.42 |ag/ml of gentamicin, respectively. 
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Discussions 
Our studies using the FME method for the investigation of PAE induced 
by antimicrobial combinations showed that the combination of rifampin and 
tobramycin against E. coli ATCC 25922 interacted in a synergistic manner on 
PAE. This was suggested by a concave FME plot (Figure 16). In addition, this 
combination produced interaction indexes (R) smaller than one thereby providing 
further evidence of a synergistic interaction. This fmding is consistent with the 
PAE data obtained in a previous study by Gudmundsson et al. (Gudmundsson, et 
al., 1991). In that study, a synergistic interaction on PAE was demonstrated in 
the tobramycin-rifampin combination against E. coli. The success of our present 
studies using the FME method to reproduce the results of an established 
interaction of antimicrobials on PAE provides proof on the validity of the FME 
method for investigating antimicrobial interactions on PAE. 
The FME method was further applied to study the interactions of two 
other antimicrobial combinations on PAE. A convex FME plot obtained for the 
ciprofloxacirVtetracycline combination against E. coli ATCC 25922 suggests an 
antagonistic interaction. Similarly, the convex FME plot also supports the basis 
for an antagonistic interaction on PAE for the ciprofloxacin/gentamicin 
combination againstPs. aeruginosa ATCC 27853. 
Studies on these thee combinations demonstrated the ability of the FME 
method in determining both synergistic and antagonistic interactions on PAE. 
In addition, the FME method is capable of determining the highest 
interactive concentration ratio for the combination studied. The highest 
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synergistic combination for rifampin plus tobramycin against E. coli ATCC 
25922 was identified to be 24.65 |ig/ml of rifampin plus 1.71 i^gAnl of 
tobramycin. The strongest antagonistic ratio for the ciprofloxacinAetracydine 
combination against E. coli ATCC 25922 and the ciprofloxacin/gentamicin 
against Ps. aeruginosa ATCC 27853 were 0.02 ^g/ml of ciprofloxacin plus 8.01 
^g/ml of tetracycline and 1.56 fig/ml of ciprofloxacin plus 2.42 pgAnl of 
gentamicin, respectively. The employment of the highest synergistic combination 
may result in a higher rate ofclinical success in chemotherapy. On the other hand, 
combinations showing the strongest antagonistic interaction should be avoided so 
as to reduce the chance of clinical failure. 
Irrespective of the types of interaction on PAE, either synergistic or 
antagonistic, all studied combinations showed increasing level ofinteraction with 
an increase in the concentrations of the more potent PAE inducing antimicrobial 
(indicated by an increase in F M E J and a simultaneous decrease in concentrations 
o f the less potent PAE-inducing antimicrobial (indicated by a decrease in FMEg) 
until a maximum interaction was obtained at 0.5 FME^+ 0.5 FMEg. Thereafter， 
further increase in concentration o f A and decrease in concentration o f B resulted 
in a decrease in interaction between the antimicrobials. 
The explanation for this specific relationship between concentrations of 
the antibiotic combination and the resulting interaction is unclear at present. 
Considering the five concentration ratios studied (Table IV)，the concentration of 
drug A increased and that of drug B decreased down the column. Provided that 
the concentration ofdrug B is high, the degree ofinteraction between drug A and 
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dmg B will depend on the limiting concentration of drug A. In other words, the 
chance ofinteraction between drug A and drug B will increase with the increase 
in concentration of dmg A until the concentration of drug B becoming the 
limiting factor (at 0.5 FME^ + 0.5 FMEg). This may be the possible reason for 
the particular observation discussed above. 
The present study has demonstrated the usefulness of the FME method 
for the study of interactions between antimicrobial combinations on PAE. 
Combinations can now be studied in a standardized manner without the need to 
employ concentrations arbitrarily. Applications of the method to other 
combinations should be further tested. 
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Table I. The MICs (in ^ig/ml) ofthe test antimicrobials forE. coli fxndPs. aeruginosa. 
Bacteria Tobramycin Rifampin Ciprofloxacin ~]| Tetracycline | Gentamicin 
F ^ 2 ^ ^ 2 -
ATCC 25922 
"7； ： ir i II Z 4 
Ps. aeruginosa - _ ^ 
ATCC 27853 
Table n. The estimated Emax, EC50 and n for the best-fit concentration-response curves for the 
antimicrobial combinations tested. 
Bacteria ~~~Antimicrobial~~~~~Emax ( l i r ) ~ ~ EC50 (x MIC) n 
combination 
T 7 ^ i Rifampin 4.78 1.54 L l? 
ATCC 25922 Tobramycin ^ ^ L1^ 
~ T e t r a c y c l i n e ~ 3.41 — 4.01 ^ 
Ciprofloxacin 1.05 0.80 7.55 
Ps. aenighiosa Gentamicin � 2 8 5 ^ i — 
ATCC 27853 Ciprofloxacin 3.89 1.56 1.59 
Table m. Concentrations ofantimicrobial combination (in ^g/ml) for PAE studies. 
Aiitimicrobial 0.2FMEA 0.4FMEA 0.5FMEA 0.6FMEA 0.8FMEA 
Bacteria Combination Antimicrobial + + + "*； � ” � � 
_0.8FMER 0.6FMEB 0-5FMEB 0.4FMEB 0.2FMEB 
� � / , . Uifnn.nin + A [Rifampm 10.05 18.96 24.65 32.04 J _ J 2 ^ 
ATCC25922 Tobramycin B Tobramycin 3.09 _ _ 2 ^ _ . _ _ L 2 i h ^ ^ ~ ~ 
Tetracycline+ 7 T Tetracycline 47.14 1 3 . 4 _ 5 _ _ _ m ^ 7 7 L ^ 
Ciprofloxacin \B Ciprofloxacm 0.017 0-019 0-020 0.021 0.024 
Pc n.m,^innsa Geiitamicin + A Gentamicin 7.72 3.40 2.42 _ _ L 7 2 ^ : Z ^ 
ATCC27853 Ciprofloxacin | B Ciprofloxacin 0�65 1.21 1.56 2.01 3.73 
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Table IV. PAEx, PAEp, and R for the antimicrobial combinations tested. 
Bacteria Antimicrobial~~ ~ PAEx PAEp R 
Combination — = = = = = = 
J ^ i A Rifampin 0.2FMEA + O-SFMEs 4.63 3.06 OM—— 
ATCC25922 B Tobramycin 0.4FMEA + 0.6FMEB 4.32 M 2 ^ — — 
0.5FMEA + 0.5FMEB 5.96 lJO ^ 
0.6FMEA + 0.4FMEB “ 4.77 一 3.92 ^ 
0.8FMEA + 0.2FMEB “ ‘ 4.74 4.35 2_22 
A Tetracycline~ 0.2FMEA + O-SFMEs ‘ 1.16 l J 2 L l l — — 
B Ciprotloxacin 0.4FMEA + 0.6FMEB 1.41 L22 h^—— 
0.5FMEA + 0.5FMEB 1-24 2.23 1.80 
0.6FMEA + 0.4FMEB ~ 1-75 ^ Lii 
| o.8FMEA + 0.2FMEB 2.36 2.94 1.25 
Ps. aeruginosa A Gentamicin~~ 0-2FMEA + O-SFMEe 3.63 3.97 1 0 ^ _ 
ATCC27853 B Ciprofloxacin 0.4FMEA + 0.6FMEB 3.13 12^ L^2—— 
0.5FMEA + 0.5FMEB H i09 l_^ 
0.6FMEA + 0.4FMEB ~ 3.07 一 4 J j h ^ 
0.8FMEA + 0.2FMEB 3.15 4.20 1.33 
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9 1 
8 3x wash ^ i > ^ J^ ^ 
:^^^l,,^u^ 
I 5 - ' 〜 " ^ 、 : ^ ^ 一 - “ 
^ • Control 
E 4 ‘ ‘ - ^ 16 p/ml Rifampin (1 MIC) 
3 - - -^»— 32 p/ml Rifampin (2 MIC) 
2 - * - 6 4 p/ml Rifampin (4 MIC) 
—*—128 p/ml Rifampin (8 MIC) 
1 --
— ^ 2 5 6 p/ml Rifampin (16 MIC) 
0 i 1 1 1 1 ~ ‘ ‘ ‘ 
0 1 2 3 4 5 6 7 8 9 
Time (hour) 
Figure 1. Growth kinetics of E. coli ATCC 25922 following one 
hour of exposure to rifampin in a series of different 
concentrations 
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9 1 — 
8 -- >^ E j / ^ X ^ " ^ ^ • Control 
3x wash y T J ^ y , 
7 B H " “ “ > � y ^ v^<^* ^ / —^3— 1 ug/ml Tobramycin 
6 & ^ ^ ^ / ^ / (�.5 MIC) 
i r ^ ^ ^ ^ ^ w _ _ V ^ 广 - ^ ^ 1 . 5 Mg/ml Tobramycin 
1 5 \ i ^ * " ‘ ^ ^ (0.75 MIC) 
^ \ \ ^ . ^ ^ ^ ^ - ^ i e - 2 pg/mi Tobramycin 
0) 4 - - I (1 MIC) 
J \ \ - ^ • 3 ng/ml Tobramycin 
3 - - \\ > ^ ^ ^ (1.5MIC) 
\ \ ^ - ^ ^ “ ^ y / ^ 6 ng/ml Tobramycin 
2 -- U ^ — ^ ^ ^ (3 M!C) 
1 -- \ ^ ^ ^ ^"^“ 8 pg/ml Tobramycin 
I——J (4 MIC) 
0 i i i i ‘ ‘ 
0 2 4 6 8 10 12 
Time (hour) 
Figure 2. Growth kinetics of E. coli ATCC 25922 following 
one hour of exposure to tobramycin in a series of different 
concentrations 
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8 ' p ^ V ^ " ^ ^ x C ^ z ；：^^^ 
g " v ^ ^ ^ • Control 
CT 4 - ® — 1 |jg/ml Tetracycline (0.5 MIC) 
J A 2 ^jg/ml Tetracycline (1 MIC) 
3 - - —X— 4 Mg/ml Tetracycline (2 MIC) 
~ * ~ 8 pg/ml Tetracycline (4 MIC) 
2 -
� 16 pg/ml Tetracycline (8 MIC) 
1 .. ~ 1 ~ 3 2 Mg/ml Tetracycline (16 MIC) 
48 pg/ml Tetracycline (24 MIC) 
oJ i i 1 j 丨 ‘ ‘ 
0 1 2 3 4 5 6 7 8 
Time (hour) 
Figure 3. Growth kinetics of E. coli ATCC 25922 following 




8 -- 3xwash . ^ > ^ ^ 
7 ' ^ = = ^ ^ ^ ^ ^ ^ ^ ^ ^ 
6 3c^ <Cf^ "^"""•"5« - ^ > ^ -^Control 
1 5 -- \ \ ^ ^ < ^ _ ^ v > / ^ / ^ - © — 0 . 0 1 2 5 pg/ml 
£ \ ^ ^ ^ ^ ' ^ ' ^ ) t ^ ^ j i r * ^ M Ciprofloxacin (0.5 MIC) 
o 4 -- * 9T - ^ 0 . 0 1 8 7 5 pg/ml 
� \ ' ^ ^ » Ciprofloxacin (0.75 MIC) 
3 - - X 0.025 pg/ml Ciprofloxacin 
(1 MIC) 
2 -- - * - 0 . 0 3 7 5 pg/ml 
Ciprofloxacin (1.5MlC) 
1 -- • 0.05 pg/ml Ciprofloxacin 
(2 MIC) 
o ' i 1 i i ‘ ‘ ‘ 
0 1 2 3 4 5 6 7 8 
Time (hour) 
Figure 4. Growth kinetics of E. coli ATCC 25322 following 





' j [ ^ P ^ ' ^ 
5 飞 \ V ^ |"^Control 
J \ \ " ^ < ~ " " X~K^^^^^ y ^ ~E3~0.5pg/mlGentamicin 
S 4 - \ \ ^ , Z (1Z8MIC) 
o) \ \ ^ / ^ y ^ j / ^ X 1 pg/ml Gentamicin 
° \ V 2 ^ i ^ ^ ^ , ^ (0.25MIC) 
3 - - r ^ {^  a ^ ^ \ C ^ ^ ^ ~*~ 2 Hg/ml Gentamicin 
\ 5 t = = = = = ^ = = " " ^ ^ ^ ^ ^ ^ ^ " ^ (0.5MIC) 
4 ^ • 4 ^ig/mI Gentamicin 
2 -• ~ ~ (1 MIC) 
~ I ~ ~ 6 pg/ml Gentamicin 
1 (1.5MIC) 
8 pg/ml Gentamicin 
(2 MIC) 
0 i H 1 1 1 ‘ 
0 2 4 6 8 10 12 
Time (hour) 
Figure 5. Growth kinetics of Ps. aeruginosa ATCC 27853 
following one hour of exposure to getamicin in a series of 
different concentrations 
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8 1 “ 
7 -- 4 • Control 
k 3xwash y J ^ 
W^S^____^^y^^ ^ , j ^ —m— 1 pg/ml Ciprofloxacin 
善^^：^^乂 （i_ 
1 \ \ \ \ ^ , . . ^ - " " ^ ^ ^ - ¥ r - 1 . 5 pg/ml Ciprofloxacin 
| . - \ \ \ _ _ / ^ (1.5MIC) 
� \ \ � � ^ K r —A 2 pg/ml Ciprofloxacin 
3.. X k _ _ ^ ^ < ^ ^ ^ ^ : : : : ^ — ) 
\ ^ > " ^ " " " " X 4 pg/ml Ciprofloxacin 
2 -- V ^ y ^ ^ - ^ (4MlC) 
1 -- ~ •~6pg /mlC ip ro f loxac in 
(6 MlC) 
o i 1 1 i ‘ ‘ 
0 2 4 6 8 10 12 
Time (hour) 
Figure 6. Growth kinetics of Ps. aeruginosa ATCC 27853 
following one hour of exposure to ciprofloxacin in a series 
of different concentrations 
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5 T “ 
• 
4.5 - ^ z ^ ^ " " ^ " " 4 - ^ " " " " • " 
4 -- , z Z ^ 
3.5 -- Z 
一 3 -- / 
I 2.5 • f ^ - / 
7 
0.5 --
o l 1 1 1 ‘ ^ 
0 50 100 150 200 250 300 
[Rifampin � (pg/ml) 
Figure 7. The concentration response curve for rifampin 
against E. coli ATCC 25922. 
Analysis was based on the sigmoidal Emax model, the 
estimated; Emax = 4.78，EC50 = 24.65 and n = 1.55. 
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3 1 — 
• 
2.5 -- ^ _ ^ " • " " " - ― ^ " “ “ 
. 2 _ _ • / , 
P - / 
1 . . / 
0.5 -- z 
/ 
0 1 ^ 1 i 1 i i 1 ‘ ^ 
0 1 2 3 4 5 6 7 8 9 
[Tobramycin] (pg/ml) 
Figure 8. The concentration response curve fortobramycin 
against E. coli ATCC 25922. 
Analysis was based on the sigmoidal Emax model, the 
estimated; Emax = 2.63, EC50 = 1.71 and n = 2.35. 
51 
8 1 “ 
: r ^ ^ 
^ 1 - 5 - 产 
Y 
o . 5 - - A 
o l 1 i 1 i ‘ ‘ 
0 5 10 15 20 25 30 35 
[ T e t r a c y c l i n e �（卯_ 
Figure 9. The concentration response curve for tetracycline 
against E. coli ATCC 25922. 
Analysis was based on the sigmoidal Emax model, the estimated; 
Emax 二 3.41，EC50 = 8.01 and n = 0.78 . 
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1.2 1 
1 广 “ ^ " • 
0.8 / 
“ 6 — Z 
‘ / 
0 .4- - i 
� 2 j 
0 1 h ^ 1 i 1 ^ 
0 0.01 0.02 0.03 0.04 0.05 0.06 
[Ciprofloxacin] (pg/ml) 
Figure 10. The concentraiton response curve for ciprofloxacin 
against E. coli ATCC 25922. 
Analysis was based on the sigmoidal Emax model, the 
estimated; Emax 二 1.05, EC50 = 0.02 and n = 7.55. 
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4.00 1 — 
3.50 -- • ^ ^ 
3.00 -- ^ ^ . ^ ^ " ^ " ^ ^ 
2.50-- ^ - ^ - ^ ^ 
^ , z 
€. 2.00 -- /Z 
^ • / • 
^ 1.50 -- Z ,/ 
1.00 -- / 
0.50 -- / 
0.00 J^ 1 1 ^ 1 1 ‘ 1 ‘~"“ 
0 1 2 3 4 5 6 7 8 9 
[Gentamicin] (^g/ml) 
Figure 11. The concentration response curve for gentamicin against 
Ps. aeruginosa ATCC 27853. 
Analysis was based on the sigmoidal Emax model, the estimated; 
Emax =4.28，EC50 = 2.42 and n = 1.20. 
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, / / ^ . 
z 
/ Z 
I / m y 
< / • 7 
乙 1 i 1 i 1 1 ^ 
0 1 2 3 4 5 6 7 
[Ciprofloxacin] (pg/ml) 
Figure 12. The concentration response curve for ciprofloxacin 
against Ps. Aeruginosa ATCC 27853. 
Analysis was based on the sigmoidal Emax model, the estimated; 
Emax = 3.89，EC50 二 1.56 and n = 1.59 • 
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9 1 
: ¾ ^ / / 
• 5 . \ ^ ^ ^ : ^ ^ r ^ " ^ I 
CT 4 \ \ ^ s ^ ^ X " ^ 0 . 2 F M E o f R i f a m p i n & 
_3 \ X EJ"">"^^Ibfc";C^^^^^^ 0.8 FME of Tobramycin 
\ , i = ^ ^ l T ' V ^ ^ ' ' ^ ^ ^ ^ -H3— 0.4 FME of Rifampin & 
3 -- ^ 0.6 FME of Tobramycin 
~ ~ ~ * ~ 0.5 FME of Rifampin & 
2 . 0.5 FME of Tobramycin 
“ " * " 0 . 6 F M E o f R i f a m p i n & 
0.4 FME of Tobramycin 
1 -- " # " 0 . 8 F M E o f R i f a m p i n & 
0.2 FME of Tobramycin 
0 1 1 i i 1 ‘ 
0 2 4 6 8 10 12 14 
Time (hour) 
Figure 13. Growth kinetics of E. coli ATCC 25922 following 
one hour of exposure to five different combinaitons of 
rifampin and tobramycin 
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_ 6 , ^ S ^ 
E 5 .. ^ v ! ^ ^ - ^ ^ ] ; ; ; ; ; i ^ ~ I ~ 0 . 8 FME of CiproHoxacin 
2 ^ ^ ^ ^^^^^^"^^ & 0.2 FME of Tetracycline 
CT 4 .. ~ ^ — 0 . 6 FME of Ciprofloxacin 
_3 & 0.4 FME of Tetracycline 
2 .. ~"‘~~0.5 FME of Ciprofloxacin 
& 0.5 FME of Tetracycline 
2 ~ 0 ^ 0.4 FME of Ciprofloxacin 
& 0.6 FME of Tetracycline 
1 ~ - # ~ 0.2 FME of Ciprofloxacin 
& 0.8 FME of Tetracycline 
0 0 1 2 3 4 5 6 7 8 9 10 
Time (hour) 
Figure 14. Growth kinetics of E. coli ATCC 25922 following 
one hour of exposure to five different combinations of 
ciprofloxacin & tetracycline 
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Figure 15. Growth kinetics of Ps. aeruginosa ATCC 
27853 following one hour of exposure to five 
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Figure 16. The FME plot for the combination of rifampin and tobramycin 
against E. coli ATCC 25922 
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Figure 17. The FME plot forthe combination ofciprofloxacin and 
tetracycline against E. coli ATCC 25922 
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Figure 18. The FME plot for the combination of ciprofloxacin and 
gentamicin against Ps. aeruginosa ATCC 27853 
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Figure 19. The interaction profile forthe combination of rifampin and 
tobramycin against E. coli ATCC 25922 
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Figure 20. The interaction profile for the combination of 
ciprofloxacin and tertracycline against E. coli ATCC 25922 
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Figure 21 • The interaction profile for the combination of gentamicin 
and ciprofloxacin against Ps. aeruginosa ATCC 27853 
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Chai3ter 3 
Effect ofsequentiaI antibiotic administration on the postantibiotic effect 
exhibited by an antimicrobial combination: A case for the combination of 
rifampin and tobramycin against E. coli ATCC 25922 
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Abstract 
The effects of the order and dosing interval between antibiotic exposure 
on PAE produced by rifampin and tobramycin which are administered 
sequentially were investigated. E. coli ATCC 25922 was exposed to rifampin for 
one hour and was followed by the second exposure to tobramycin at the 
beginning, in the middle and at the end of the postantibiotic phase produced by 
rifampin. The study was repeated with the order of antimicrobial exposure 
reversed. In the order of tobramycin followed by rifampin, this antimicrobial 
combination produced an additive PAE regardless of the timing of rifampin 
exposure. For the reverse order, tobramycin added within the postantibiotic 
phase generated an antagonistic interaction on PAE. Such antagonism 
disappeared towards the end of the postantibiotic phase of rifampin. It was 
therefore observed that both the order and interval of drug exposure in a 
sequential manner affected the PAE. Whenever sequential administration o f the 
antimicrobial combination is adapted, the order and the interval of antimicrobial 
administration must therefore be considered carefully. In addition, the 
administration of the antimicrobial within the postantibiotic phase should be 
avoided because of the possibility that an antagonistic effect on PAE may occur. 
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Introduction 
When antimicrobial combination therapies are used in clinical settings, 
the initial dosing of the antimicrobials is usually administered simultaneously. 
This is normally done for the convenience of administration. However, due to 
the difference in the dosing regimens of the two antibiotics, or for certain 
reasons, subsequent doses of the combinations are usually administered 
sequentially. For instance, because of the incompatibility between penicillin and 
aminoglycoside, the two antibiotics are successively administered rather than 
mixed for simultaneous dosing. 
When antimicrobials within a combination are administered separately, 
the order ofeach drug administration can vary and their doses may be separated 
by different time intervals. When deciding the optimal dosing schedules for 
antimicrobial combination given sequentially, the two aspects above must be 
considered. 
Although studies designed to investigate the effect of sequential dosing 
on the activities of antimicrobial combination are valuable in aiding dosing 
regimen design, limited studies have been conducted (Haller, 1982; 
Guggenbichler et al., 1988; Dudley et al.，1991; Oka et al., 1993; Barclay et al., 
1995) in this area. All of these studies have illustrated only the effect of 
sequential administration on the killing and inhibitory activities of the 
antimicrobial combination. Some of these studies showed that the order of 
administration has no effect on the bactericidal activities of the antibiotic 
combination (e.g. azlocillin & sisomicin against Ps. aeruginosa by Haller, 1982; 
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gentamicin & ampicillin against E. coli by Konig, et al.，1986). Whereas other 
studies showed that the order of administration indeed produced significant 
effect on the killing activities of the combinations (e.g. cefotiam & imipenem 
against S. aureus by Oka et al., 1993 and gentamicin & ceftazidime against Ps. 
aeruginosa ATCC 27853 by Barclay et al., 1995). In the studies investigating 
the effect of administration interval on the inhibitory activities of antimicrobial 
combinations, Oka et al. (Oka et al., 1993) showed that the delay in regrowth on 
the surviving bacteria reduced with an increase in the dosing interval. However, 
Barclay et al. (Barclay et al., 1995) demonstrated that the delay in regrowth 
prolonged with the increasing dosing interval up to a certain point and then 
remained constant thereafter. Results obtained from these studies were 
inconsistent. Conclusions regarding the effect of sequential administration of an 
antimicrobial combination on its activities were therefore difficult to determine. 
Previous studies on sequential administration have focused on studying 
the inhibitory or killing activities of the antimicrobial combination. However, 
the effect of sequential administration on the postantibiotic effect has not been 
studied. Although some of these studies have reported the delayed regrowth 
produced by antimicrobial combination, the study design was not engineered to 
study PAE specifically. To provide more practically useful information for the 
design of dosage regimen for antimicrobial combination that are administered 
sequentially, our present studies were designed to reveal the effect of sequential 
administration on the postantibiotic effect exhibited by antibiotic combinations. 
In previous studies, arbitrary dosing intervals for the study antimicrobials 
68 
were selected for sequential administration studies. A systematic approach for 
the selection ofdosing interval has not been established. This makes comparison 
ofresults from studies using different dosing intervals impossible. 
Studies investigating the killing activity of antimicrobial during the 
postantibiotic phase showed a decrease in killing during the postantibiotic phase 
(Gudmundsson et al., 1994). Studies comparing the sub-MIC effect (SME) on 
untreated culture and that on previously exposed culture (PASME) demonstrated 
that although the sub-MIC effect on untreated culture was negligible, those on 
previously exposed culture produced a significant prolongation in PAE. Both 
studies illustrated that the state of growth of bacteria (e.g. stationary phase or 
logarithmic-growth phase) affects both the bactericidal activity and PAE 
produced by an antimicrobial. However, the importance of these states of 
growth of bacteria has been neglected in previous studies on sequential 
administration. Furthermore, in these studies, the length of the administration 
interval has been considered to be the major influence on the antimicrobial 
activities. 
In response to these problems, a systematic approach considering the 
states ofgrowth ofbacteria as the basis for standardizing the dosing intervals for 
sequential administration studies on PAE is proposed here. 
In our experiments, bacteria were exposed to the first antimicrobial for 
one hour. This was followed by the administration of the second antimicrobial at 
the start, in the middle and at the end of the postantibiotic phase generated by 
the first antimicrobial. The states ofbacteria within the postantibiotic phase were 
69 
used to define the administration interval. Compared to the arbitrary 
administration intervals used in previous studies, our present design employed a 
logical basis for standardizing the administration interval for sequential 
administration studies which allows comparisons of results between studies. 
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Materials and Methods 
Antimicrobial-organism combination 
Rifampin in combination with tobramycin was tested against E. coli 
ATCC 25922. The concentration ratio of this combination used in this study has 
been shown to yield the highest synergistic interaction (the one with the smallest 
interaction index) in chapter 2 ofthis thesis. The concentrations for rifampin and 
tobramycin tested were 24.65 ^ig/ml and 1.71 ugAnl，respectively. This was 
selected to allow the effect of sequential administration with respect to a clear 
synergistic combination to be determined. The test organism was E. coli ATCC 
25922. The antimicrobials were purchased from Sigma Chemical Co., St. Louis 
and the organism was purchased from Difco Laboratories, Detroit, Michigan. 
Culture media 
Mueller Hinton broth and nutrient agar (Difco Laboratories, Detroit 
Michigan) were used. Mueller Hinton broth was supplemented with 12.5ngAnl 
ofMg2+ and 25 ^ig/ml ofCa?+ according to the recommendation from National 
Committee for Clinical Laboratory Standards. Both media were sterilized by 
autoclaving as recommended by the manufacturer. 
Organism 
The test organism was isolated and then subcultured on agar slants. To 
ensure consistency ofresults, one colony was selected and kept on agar slants at 
4 °C before the experiments. 
On the day before each experiment, bacteria from the agar slant were 
transferred to broth and allowed to grow overnight at 37 °C. On the day of the 
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experiment, the overnight culture was diluted with fresh pre-warmed broth by 
1000-fold and then incubated at 3 7 � • for 2-2.5 hr. This allowed the bacteria to 
q 
reach the logarithmic-growth phase and to attain an inoculum o f � 1 0 cfU/ml 
prior to initiation of the experiments. 
Antimicrobials 
Stock solutions of the antimicrobials studied at concentration ten times 
that required for the experiments were prepared according to the 
recommendations from the manufacturer. 
Determination of postantibiotic effect. 
PAE was determined by following the growth kinetics of the bacteria 
after antimicrobial exposure. The colony counting method was used to 
quantitate viable bacteria. 
To start the experiment, bacteria in the logarithmic-growth phase were 
exposed to the first antimicrobial at 37 °C for one hour. This was achieved by 
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adding one ml ofthe bacteria in the logarithmic-growth phase (-10 cfu/ml) to 9 
ml of antimicrobial containing medium and this resulted in an initial inoculum 
of � l o 6 cfu/ml. At the end of one-hour incubation, the antimicrobial was 
removed by 3x washing with sterile 0.9% NaCl solution and centrifugation at 
2500 rpm for 10 minutes. The cell pellet was reconstituted with pre-warmed 
broth and incubated at 37 °C. 
The second antibiotic was then added at the beginning, in the middle or 
at the end of the postantibiotic phase produced by the first antibiotic. In this 
case, 1 ml ofthe second antibiotic solution was added to 9ml of the pre-exposed 
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culture following the removal of the first antibiotic. Similar to the first exposure, 
the culture was exposed to the second antibiotic at 37 °C for one hour. At the 
end of the exposure, the antibiotic was once again removed by washing with 
sterile saline. After completion ofthe antibiotic removal process, the culture was 
reincubated at 37 T . Bacterial regrowth was followed by sampling at the start of 
the experiment, prior to and immediately after each drug removal and every 
hour thereafter until enough data were collected to allow PAE determinations. 
Viable counts were determined by microdilution method on agar. Colony counts 
were recorded after 18 hour incubation at 37 °C and were plotted as Log viable 
counts (cfu/ml) against time. PAE was estimated according to the equation: PAE 
二 T-C, where T is the time required for the viable count in the test culture to 
increase by one log^o unit above the count observed immediately after drug 
removal and C is the time required for the viable count in the antibiotic free 
control culture to increase by one \og^^ unit above the count observed 
immediately after identical drug removal procedures. 
The control cultures were diluted by 10-100 fold at the time of the 
second antibiotic challenge so as to ensure logarithmic-growth throughout the 
experiment. All experiments were performed in triplicate. 
73 
Results 
The PAEs induced following an one-hour exposure to 1.71 ^g/ml 
tobramycin, 24.65 ^ig/ml rifampin, either alone or in combination，and the 
additive PAE of the combination against E. coli ATCC 25922 are shown in 
Table I. The PAE induced by tobramycin and rifampin individually were 1.51 土 
0.10 and 2.96 士 0.05 h respectively. Simultaneous exposure to both antibiotics 
resulted in a PAE of4.99 士 0.25 h. In fact, this PAE was longer than the additive 
PAE for the combination i.e.,4.47 h. By definition, synergism was observed for 
this combination. 
In our present studies, E. coli ATCC 25922 was subjected to sequential 
exposure to rifampin and tobramycin (Figure 1). The effect of this sequential 
exposure in two different orders, i.e., tobramycin followed by rifampin and the 
reverse order were studied. The PAEs produced by the second antimicrobial as a 
result of various administration schedules are shown in Table II. The PAEs 
produced by tobramycin added at the beginning, in the middle and at the end of 
the postantibiotic phase generated by previous rifampin exposure were 2.57 土 
0.28, 1.51 士 0.16 and 1.70 士 0.28 h, respectively. The PAEs produced by 
. rifampin following prior tobramycin exposure were 4.73 士 0.35，3.73 士 0.66 and 
3.11 士 0.35 h, respectively. Regardless of the order of administration, the PAEs 
produced by the antimicrobials added at the beginning, in the middle or at the 
end o f the postantibiotic phase appeared to decrease throughout the PAE phase. 
The PAEs generated by the antimicrobials added at the beginning of the 
postantibiotic phase (tobramycin: 2.57 土 0.28 h, rifampin: 4.73 士 0.35 h) are 
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comparatively longer than those produced by the culture without pre-exposure to 
antimicrobial (tobramycin: 1.51 士 0.10 h, rifampin: 2.96 士 0.05 h). Those 
induced by the antimicrobials added at the end of the PAE phase (tobramycin: 
1.70 士 0.28 h，rifampin: 3.11 士 0.35 h) returned to the same value as those 
induced on the culture without pre-exposure. Compared to the additive PAE 
showed by the combination (4.51 h), the PAE produced by tobramycin added at 
the beginning of the PAE phase induced by rifampin (2.57 土 0.28 h) was 
comparatively shorter. The PAEs produced by rifampin added right after 
tobramycin exposure, i.e., 4.73 士 0.35 h was similar to the additive PAE. 
The overall PAEs produced by the sequential administration of rifampin 
and tobramycin are presented in Table III. A significant difference in PAEs 
produced by different orders of administration was observed. When the order of 
tobramycin followed by rifampin was studied, irrespective of the time of 
administration o f the second antimicrobial, the overall PAEs generated (4.73 h， 
4.49 h and 4.62 h) were similar to the additive PAE for the combination (4.47 
h). As with the reversed order, both the time and order of administration affected 
the overall PAE. Except the PAE produced by tobramycin added at the end of 
the PAE phase of rifampin (4.66 h) was similar to the additive PAE for the 
combination, the overall PAEs generated (2.57 h, 2.99 h and 4.66 h) by this 
reversed order increased over the PAE phase and were much shorter than the 
additive PAE. By conventional definition of interaction, the first order of 
administration (i.e. tobramycin followed by rifampin), induced PAEs similar to 
the additive PAE irrespective of the time of the second antimicrobial exposure. 
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Whereas, the second order of administration, i.e. rifampin followed by 
tobramycin, with tobramycin administered within the postantibiotic phase, 
produced PAEs that were comparative shorter than the additive PAE. The extent 
for this apparent antagonistic interaction decreased from the beginning till the 
end of the postantibiotic phase induced by rifampin. With this order of 
administration，rifampin followed by tobramycin administered at the end of the 
postantibiotic phase produced an additive PAE. 
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Discussions 
Studies on the postantibiotic sub-MIC effect have shown that 
antimicrobial at sub-MIC level added during the postantibiotic phase induced a 
significant prolongation of its PAE, though the direct sub-MIC effect on the 
suppression of bacterial growth is negligible (Odenholt-Tornqvist, 1991; 
Odenholt-Tornqvist, 1993; Odenholt-Tornqvist & Bengtsson，1994). In view of 
this finding, challenge to the bacteria by antibiotic during the postantibiotic 
phase may result in the prolongation of PAE. Clinically, such prolongation in 
PAE may have important implications on extending the normal dosing interval. 
Unfortunately, in our present studies, such prolongation in PAE was not 
observed. Apparently, the administration of antimicrobials at the beginning of 
the postantibiotic phase produced PAE longer than that of the culture without 
previous exposure to antibiotic provides support for the advantage of 
administering antimicrobial during the PAE phase. However, considering the 
overall PAE produced by the antimicrobial combination, sequential 
administration ofantimicrobials during the PAE phase produced only additive or 
antagonistic PAE, no matter if the second antimicrobials were administered at 
the beginning, in the middle or at the end of the PAE phase of the first agent. 
Therefore, the advantage of administering antimicrobials during the 
postantibiotic phase in sequential administration over simultaneous 
administration of antimicrobial combination was not observed. As with the 
study on the administration order of tobramycin followed by rifampin， 
irrespective of the time of the second antibiotic challenge, the overall PAEs 
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were comparable to the additive PAE produced by the combination. Synergistic 
PAE produced by simultaneous administration of the combination could not be 
obtained by these sequential administration schedules. For the reversed order of 
administration, i.e., rifampin followed by tobramycin, with tobramycin added 
within the postantibiotic phase ofrifampin, the overall PAEs were shorter than 
the additive PAE and was much shorter than the synergistic PAE produced by 
simultaneous administration of the combination. In other words, antagonistic 
interaction on PAE was obtained. These observations showed that 
administration of antimicrobial during the postantibiotic phase can not help 
prolong the overall PAE generated by the tobramycin and rifampin combination 
against E. coli ATCC 25922. 
Based on our present preliminary studies, the PAE produced by 
sequential and simultaneous administration should be measured for comparison, 
when one decides to extend the administration interval of antimicrobial 
combination by a time period equal to PAE. In this case for rifampin and 
tobramycin, the normal independent dosing schedules for individual 
antimicrobials should be avoided. Otherwise, antimicrobial administration 
within the PAE phase of another antibiotic may occur and this may adversely 
affect the PAE produced by the combination. For the present case, if sequential 
administration of antimicrobials is necessary, dosing of the second antibiotic at 
the end of the PAE phase induced by the first one is recommended. This 
administration schedule can at least ensure additive PAEs be obtained. 
Our studies showed that both the order and the interval of drug 
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administration in sequential administration affect PAE. Whenever sequential 
administration of antimicrobial combination is adapted, the order and the 
interval of dmg administration must be considered carefully. With the 
combination of rifampin and tobramycin against E. coli ATCC 25922, the 
administration oftobramycin should followed by that of rifampin throughout the 
PAE phase produced by previous tobramycin exposure and so ensure the 
additive PAE produced by the combination. With the reversed order, the 
administration of tobramycin should take place at the end of the postantibiotic 
phase induced by rifampin such that an additive PAE can only be obtained. 
Because of the production of an antagonistic effect on PAE, the administration 
oftobramycin within the PAE phase of rifampin is not recommended. 
Studies on the PAE produced by repeated exposure to the same antibiotic 
have shown that PAEs for some antibiotics shortened after repeated exposure 
(Karlowsky et al.，1993; Magrath, 1993; Karlowsky et al., 1994). This may 
adversely affect the clinical significance of PAE. Data obtained in the present 
studies showed that the PAE produced by an antimicrobial against bacteria that 
had recovered from previous exposure to another antimicrobial, i.e.，at the end 
of the PAE phase, was similar to that produced on the control without pre-
exposure to antimicrobials. This indicates that alternating antimicrobial therapy 
may enable the PAEs to remain constant throughout repeated dosing. Further 
studies to show the administration of antimicrobials in an alternating manner as 
a means to maintain PAEs produced by antimicrobials throughout the therapy 
are necessary. 
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Apart from our present studies on the timing of antimicrobial 
administration, the effects of interaction time between antimicrobials and also 
the effect of concentration and time of the first antimicrobial exposure on either 
the PAE or other antimicrobial activities should also be studied in order to 
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Figure 1. The sequential administration schedules for rifampin and tobramycin. 
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Table I. PAE produced by one hour exposure to 24.65 ^ig/ml rifampin, 1.71 ^igAnl tobramycin 
either alone or in combination against E. coli ATCC 25922 
Antimicrobials Tobramycin Rifampin Tobramycin <feRifampin 
PAE 1.51土0.1011 2 .96±0 .05h 4 .99±0.25 1i | 
* The additive PAE for the combination of tobramycin & rifmnpin against E. coli ATCC 25922 
after one hr exposure is 4.47 h (sum of the PAE produced by tobramycin and rifampin) 
Table II. Effect ofthe order and the time ofadministration on PAE produced by the second 
antimicrobial in the sequential exposure to the combination of rifampin and tobramycin against 
E. coli ATCC 25922 
Sequence fo r~~ Time of the addition of the 2nd antimicrobial 
antimicrobial At the beginning of 11 In the middle of At the end of the 
exposure the PAE phase the PAE phase PAE phase 
1： Rifampin 2.57±0.28 h ~ ~ ~ ~ 1 . 5 1 t 0 . 1 6 h ~ ~ | 1 .70±0 .28h 
2: Tobramycin 
1: Tobramycin ~ ~ 4 . 7 3 ± 0 . 3 5 h ~ ~ ~ 3.73±0.66 1i 3 . i l ± 0 . 3 5 h 
2: Rifampin 
Table III. Effect ofthe order and the time ofadministration on the overall PAE produced by 
sequential exposure to the combination of rifampin and tobramycin against E. coli ATCC 
25922 
Sequence for~~ Time of addition of the 2nd antimicrobial 
antimicrobial At the beginning In the middle of Atthe end of the 
exposure ofthe PAE phase the PAE phase PAE phase 
1： Rifampin 2.57 h 2.99 h 4.66 h 
2: Tobramycin 
1: Tobramycin 4.73 h 4.49 h 4.62 h 
2: Rifampin 
P.S. For raw data of the above three tables, please refer to Appendix IV. 
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Chanter 4 
Effect ofantimicrobial resistance to the components ofan antimicrobial 
combination on the postantibiotic effect exhibited by an antimicrobial 




The PAE produced by the representative synergistic combination， 
piperacillin and gentamicin against Ps aeruginosa was investigated. Standard 
(ATCC 27853) and resistant strains (induced by the two antibiotics individually) 
were tested. Against piperacillin-resistant Ps. aeruginosa (resistance of0 .5 MIC 
to 2 MIC), the antimicrobial combination produced a synergistic PAE (range 
from 2.47 to 2.62 h) comparable to that observed for the standard strains ofPs. 
aeruginosa (2.46 h). On the contrary, the combination produced PAE of 1.79 h 
when tested against gentamicin-resistant Ps. aeruginosa (resistant to 0.5 MIC of 
gentamicin). As gentamicin resistance in Ps. aeruginosa increased from 1 \xglm\ 
to 4 ^ig/ml (from 0.5 MIC to 2 MIC), the PAE produced by the combination 
decreased from 1.79 h to 0.42 h. As a result of such a minor change in 
gentamicin resistance，the PAE produced by this combination decreased from an 
obvious synergistic PAE to an insignificant level. Therefore, the synergistic 
PAE produced by the piperacillin-gentamicin combination against Ps 




Bacterial resistance is a global problem concerning public health (Russel 
& Chopra, 1990; Neu, 1992). The accelerating evolution ofbacteria into strains 
resistant to the systemic antimicrobial therapies has rendered many antibiotics 
ineffective 0^eu, 1992; Alexander, 1994; Thornsberry, 1995). In order to 
combat infections caused by resistant bacteria, new antimicrobials are being 
developed. However, the development of clinically safe and effective new 
agents takes a long time. Therefore, in parallel to the new drug research, 
intensive studies are being carried out on presently available antimicrobials to 
search for alternate single or combination therapy to cope with fast developing 
bacterial resistance. Understanding of the changes in antimicrobial 
pharmacodynamics with respect to resistance is increasingly urgent. Our present 
study aims at studying the effect of antimicrobial resistance on the PAE 
exhibited by a representative antimicrobial combination. 
In our study, the effects of the type and extent of antimicrobial resistance 
on the PAE of a synergistic penicillin and aminoglycoside combination，i.e., 
piperacillin and gentamicin, against Ps. aeruginosa were investigated. Clinical 
isolates are commonly used to study the PAE of antimicrobial combinations 
against resistant bacteria. This practice seriously limits the effects of the type 
and extent of antimicrobial resistance on the PAE exhibited by antimicrobial 
combinations to be determined (Fuursted, 1987; Fuursted, 1988; Fuursted, 1989; 
Winstenley & Hasings, 1989; Gudmundsson, 1991). To enable the effects of 
antimicrobial resistance, including the effects of the type and extent ofresistance 
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to be examined, a number of organisms with increasing levels of resistance to 
the individual antimicrobials studied were used in our current study. These 
resistant organisms were induced by serial passages to two-fold increasing 
concentrations of the antimicrobials. 
Ps. aeruginosa resistant to either piperacillin or gentamicin was 
subjected to one-hour exposure to piperacillin and gentamicin either alone or in 
combination. The PAEs induced under different antibiotics were determined. 
Through comparative studies on the PAEs produced by these resistant 
organisms, the effects of the levels of either piperacillin or gentamicin resistance 
on the PAE induced by the piperacillin/gentamicin combination were revealed. 
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Materials and Methods 
Antimicrobial-organism comhination 
A representative synergistic antimicrobial combination, piperacillin and 
gentamicin was used to test against Ps. aeruginosa with various levels of 
resistance to the two antibiotics. 32 ^ig/ml of piperacillin and 1 ^ig/ml of 
gentamicin demonstrated by preliminary studies to interact synergistically on 
PAE were used throughout our studies. The antimicrobials were purchased from 
Sigma Chemical Co., St. Louis and the organism was purchased from Difco 
Laboratories, Detroit, Michigan. 
Culture media 
Mueller Hinton broth and nutrient agar purchased from Difco 
Laboratories, Detroit, Michigan，were used. The broth was supplemented with 
12.5^ig/ml o f M g 2 + and 25 |ag/ml o f C a ^ + according to the recommendation 
from the National Committee for Clinical Laboratory Standards. Both media 
were sterilized by autoclaving as recommended by the manufacturer. 
Organisms 
A number of Ps. aeruginosa bacteria with increasing resistance to either 
piperacillin or gentamicin were prepared by serial passages to two-fold 
increasing concentrations o f the two individual antimicrobials. The passage was 
started at 0.5MIC and then extended to lMIC and 2MIC of each of the 
antimicrobials. Following these induction procedures, Ps. aeruginosa that were 
resistant to 16^ig/ml, 32 ^ig/ml & 64 ^ig/ml (0.5 MIC, 1 MIC & 2 MIC, 
respectively) of piperacillin and those strains that were resistant to 1 ^g/ml, 2 
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|igAnl & 4 ^ig/ml (0.5 MIC, 1 MIC & 2 MIC, respectively) of gentamicin were 
prepared. 
On the day of the experiment, the resistant bacterial culture was diluted 
by 1000-fold with fresh broth and then incubated at 3 7 � C for 2-2.5 hr. This 
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allowed the bacteria to reach logarithmic-growth and an inoculum of � 1 0 
cfu/ml for the experiments. 
Antimicrobials 
32 ^ig/ml of Piperacillin, 1 ^ig/ml of gentamicin either alone or in 
combination were used in our studies. Antimicrobial stock solutions with 
concentration ten times that required for the experiments were prepared 
according to the recommendations by the manufacturer. 
Determination ofpostantihiotic effect 
The growth kinetics of the organisms after antimicrobial exposure were 
followed by colony counting method for PAE determination. 
PAEs produced by piperacillin, gentamicin either alone or in 
combination against the organisms at different levels of resistance (0.5MIC, 
lMIC, 2MIC) were determined. For each PAE determination, resistant 
organisms in logarithmic growth were exposed to the studied antibiotics at 37 °C 
y 
for one hour. One ml of the actively growing resistant organism ( � 1 0 cfb/ml) 
was added to the antimicrobial containing medium to produce an initial 
inoculum of � 1 0 ^ cfu/ml. At the end of the one-hour incubation, the 
antimicrobial was removed by washing with sterile 0.9% NaCl solution (3x) and 
centrifugation at 2500 rpm for 10 minutes. The cell pellet was reconstituted with 
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pre-warmed broth and reincubated at 3 7 � C . Bacterial regrowth of the cultures 
was followed by sampling at the start of the experiment, prior to and 
immediately after drug removal and every hour thereafter until enough data 
were collected to allow PAE determination. Viable counts were determined by 
microdilution method on agar. The results were recorded after 18 hour of 
incubation at 3 7 � C and plotted using Log viable counts (cfu/ml) against time. 
PAE was calculated according to the equation: PAE = T-C，where T is the time 
required for the viable count in the test culture to increase by one log!o unit 
above the count observed immediately after dmg removal and C is the time 
required for the viable count in the antibiotic-free control culture to increase by 
one logio unit above the count observed immediately after the identical drug 
removal procedures. 
The use of the control ensures that any delay in regrowth observed for 
the test cultures caused by factors other than antimicrobial exposure (e.g. 
mechanical disturbance, temporary deprivation of nutrients and abrupt 
temperature changes resulting from the dmg removal process) were excluded in 
the PAE determination. 
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Results 
The PAE produced by piperacillin, gentamicin either alone or in 
combination against the reference strain, Ps. aeruginosa ATCC 27853 and the 
induced gentamicin-resistant Ps. aeruginosa are shown in Table 1. For Ps. 
aeruginosa ATCC 27853, piperacillin, gentamicin and their combination 
induced a PAE of-O.lOh and 1.33h and 2.46h, respectively. The PAE induced 
by the combination (2.46 h) was comparative longer than the sum of the PAE 
induced by individual antimicrobials (-0.10 h + 1.33 h 二 1.23 h). In other words, 
a synergistic PAE was produced by the antimicrobial combination. 
As with Ps. aeruginosa that was resistant to 1 ^igAnl of gentamicin 
(0.5MIC), piperacillin, gentamicin and their combination produced a PAE of 
0.48hr, 0.86hr and 1.79hr, respectively. Compared with the corresponding PAEs 
produced onPs. aeruginosa ATCC 27853, PAE produced by piperacillin against 
Ps. aeruginosa (resistant to 1 ^ig/ml of gentamicin) was slightly longer, whereas 
the PAEs produced by gentamicin and the piperacillin-gentamicin combination 
were shorter. As the gentamicin resistance on Ps. aeruginosa increased from 
0.5MIC to 2MIC, the PAEs produced by piperacillin did not increase any further 
and remained within the range ofO.48-0.81 hrs. However, coupled with such 
decreases in gentamicin resistance, the PAEs produced by gentamicin decreased 
from 0.86h to a negligible level (Table II). Similarly, the PAEs produced by the 
piperacillin-gentamicin combination decreased from 1.79h to 0.42h (Table II). 
Even a minor change in gentamicin resistance (from 0.5MIC to 2MIC) caused 
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the synergistic PAEs produced by the piperacillin-gentamicin combination to 
decrease significantly. 
In contrast to the drastic effects of gentamicin resistance, the effect of 
piperacillin resistance on the PAE induced by piperacillin and gentamicin either 
alone or in combination were insignificant. As shown in Table II，the PAE 
produced by piperacillin on Ps. aeruginosa that were resistant to 16^g/ml, 
32^ig/ml and 64^ig/ml of piperacillin (0.5MIC, lMIC, 2MIC) were -0 .06h, -
0.03h and -0.06h, respectively. The PAEs measured were similar to that 
documented for Ps. aeruginosa ATCC 27583. Similarly, the PAEs produced by 
the piperacillin-gentamicin combination on all piperacillin-resistant Ps. 
aeruginosa strains (2.47h, 2.51h and 2.62h) were comparable to that of Ps. 
aeruginosa ATCC 27853 (2.46h). In both cases, a negligible effect of 
piperacillin resistance on the PAEs induced by piperacillin alone and 
piperacillin-gentamicin combination was observed. On the other hand, 
piperacillin resistance showed an effect on the PAE produced by gentamicin. 
Compared to the PAE produced by gentamicin against Ps. aeruginosa ATCC 
27853 (1.33h), PAE produced by gentamicin against Ps. aeruginosa (resistant to 
16^ig/ml of piperacillin) was longer. With an increase in piperacillin resistance 
from 16^ig/ml to 64^ig/ml (from 0.5MIC to 2MIC), the PAEs produced by 
gentamicin did not increase further and remained in the range between 2.32-
2.6h. 
Against all piperacillin-resistant strains, the PAEs produced by 
piperacillin were close to zero; whereas, the PAE produced by gentamicin 
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(range from 2.32 to 2.60 h) were similar to that produced by the combination 
(range from 2.47 to 2.60 h). According to the normal qualitative definition for 
interactions, the interaction between piperacillin and gentamicin against 
piperacillin-resistant strains may be classified as either indifferent or additive. 
Whatever the type of interaction being classified for these piperacillin-resistant 
strains, PAEs similar to the synergistic PAE (2.46 h) observed for Ps. 
aeruginosa ATCC 27853 were produced by the combination. 
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Discussions 
Results o four studies showed that the PAE produced by the combination 
of piperacillin and gentamicin against Ps. aeruginosa depended on the type of 
resistance to the individual antibiotics. Piperacillin resistance induced on Ps. 
aeruginosa (0.5 MIC to 2 MIC) did not affect the PAE produced by the 
combination. On the contrary, a drastic effect was observed when gentamicin 
resistance was induced. Compared to the reference strain, Ps. aeruginosa ATCC 
27853, gentamicin resistance at 1 ^ig/ml (0.5 MIC) resulted in a decrease in the 
PAE produced by the combination from 2.46 h to 1.79 h. The increase in 
gentamicin resistance from 0.5 MIC to 2 MIC resulted in a further decrease of 
the PAE from 1.79 h to 0.42 h. As a result, the synergistic effect on PAE 
produced by the piperacillin-gentamicin combination decreased significantly. 
Studies from Fuursted，（Fuursted, 1987; Fuursted，1988; Fuursted，1989) 
and Winstanley & Hastings, (Winstanley & Hastings, 1989) on the penicillin-
aminoglycoside combinations against clinical isolates of enterococci showed 
that a synergistic interaction on PAE or prolongation in PAE (> 0.5 h) was 
observed only in aminoglycoside-susceptible strains. When the aminoglycoside-
resistant strains were tested, synergism on PAE was not observed. In agreement 
with these findings, our studies illustrate that aminoglycoside resistance but not 
penicillin resistance is the major determinant for the synergistic PAE produced 
by the penicillin-aminoglycoside combination. Independent of the piperacillin 
susceptibility, either susceptible or resistant, PAEs comparable to the synergistic 
PAE produced on Ps. aerngwosa ATCC 27853 were induced by the 
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combination of piperacillin and gentamicin. However, the synergistic PAE 
produced by the combination decreased significantly (from 1.79 to 0.42 h) when 
gentamicin resistance increased from 0.5MIC to 2MIC. As observed from the 
regrowth kinetics of the gentamicin resistant strains that followed one hour of 
exposure to the combination, such reduction in the PAE produced by the 
combination was associated with a significant decrease in killing produced by 
the combination (Figure 1). This actual reduction in killing means a decrease in 
damage on the test bacteria, which in turn may explain the decrease in recovery 
time (PAE) required by the bacteria to return to normal state. (PAE is believed 
to be the time required by bacteria to recover from damages caused by previous 
exposure to antimicrobials. The length of this recovery time should depend on 
the extent of damage imposed on the bacteria. Heavy damage requires longer 
time for bacteria to recover to normal state and vice versa.) 
Due to the presence of synergistic interaction on PAE, gentamicin-
susceptible Ps. aeruginosa, regardless of its piperacillin susceptibility, is 
recommended to be treated with extended dosing interval of piperacillin and ‘ 
gentamicin. However, Ps. aeruginosa that is resistant to gentamicin is advised to 
be treated with normal dosing schedule because only a small change in the 
susceptibility for gentamicin caused a reduction in the PAE produced by the 
combination to an insignificant level. To determine whether similar effects 
caused by antimicrobial resistance occurred in all penicillin-aminoglycoside 
combinations, further studies should be extended to more aminoglycoside-
penicillin combinations. 
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PAE data are valuable for the design of dosage regimens. However, the 
process of obtaining such data is cumblesome. Correlation studies on the PAE 
and MIC may be established to investigate whether a correlation between the 
MIC and the PAE can be formulated. The success in defining such relationships 
may promote more accurate prediction o fPAE as a function ofMIC. By doing 
so, simplification of the process ofutilizing PAE to aid dosage regimen design 
can be achieved. 
The use of limited levels of resistance should be followed up by further 
studies with broader resistance coverage. In addition, this may allow the 
characteristic pattern ofPAE produced by antimicrobial combination against the 
resistance strains demonstrated in our present study to be further determined. 
The contribution ofresistance to PAE and thus optimal antimicrobial use should 
be verified in future studies. 
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Table I. PAE (hours) produced by one-hour exposure to 32 ^ig/ml of piperacillin，1 Hg/ml of 
gentamicin and in combination on Ps. aeruginosa ATCC 27853. 
I Bacteria Piperacillin Gentamicin Piperacillin & Gentamicin 
I Ps. aeruginosa ^ ^ 1.33 2.46 
I ATCC 27853 
Table 11. PAE (hours) produced by one-hour exposure to 32 ^ig/ml ofpiperacillin, 1 ng/ml of 
gentamicin and in combination on both reference {Ps. aeruginosa ATCC 27853) and 
gentamicin resistant strains. 
~~Concentration of Piperacillin Gentamicin Piperacillin & 
gentamicin that Gentamicin 
induced resistant Ps. 
aeruginosa “ig/ml) 
"""Ps. aeruginosa~~ -0.10 i.33 2.46 
ATCC 27853 
1 (0.5 MIC) 0.48 O M L25 
2 (1 MIC) 0.81 0.58 LiZ 
4 ( 2 ^ C ) 0.53 -0-24 0.42 
* MIC of gentamicin against Ps. aeruginosa ATCC 27853 is 2 ^ig/ml 
Table III. PAE (hours) produced by one-hour exposure to 32 ^ig/ml ofpiperacillin, 1 ^ig/ml of 
gentamicin and in combination on both reference {Ps. aeruginosa ATCC 27853) and 
piperacillin resistant strains. 
~"Concentration of ~~Piperaci l l in Gentamicin ~~Piperaci l l in & 
piperacillin that Gentamicin 
induced resistant Ps. 
aeruginosa 
(^tg/ml) = = = = = — = — — — 
~ ~ P s . aeruginosa~~ ^ ~ ~ ~ ~ ^ ^ 2.46 
ATCC 27853 
16 (0.5 M I Q ~ ~ -0.06 2.45 ^ 
32 (1 MIC) -0.03 2.32 ^ 
64 (2 MIC) � -0.06 2.60 2.62 
* MIC ofpiperacillin against Ps. aeruginosa ATCC 27853 is 32 ^ig/ml 
p. S. For raw data of the above three tables, please refer to Appendix V. 
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Figure 1. G r o w t h kinet ics of Ps. aeruginosa A T C C 
27853 and gentamic in - res is tant stra ins f o l l o w i n g one 
hour of exposure to the c o m b i n a t i o n of 32 pg /ml 






After the discovery of the potential impact of PAE on the design of 
dosing regimens for antimicrobials, a large number of studies has been 
conducted to determine the PAE for a wide variety of antimicrobials and 
organisms which are attempted to provide theoretical bases for the design of 
dosing regimens for antimicrobials. Despite intensive studies, the importance of 
antimicrobial combinations has not been realized. Therefore our present project 
aims at studying the PAEs exhibited by antimicrobial combinations. 
The FME method has been employed in our current studies to investigate 
the PAEs exhibited by antimicrobial combinations. Using the experimentally 
defined concentration-response curves for individual antimicrobials to determine 
the additivity, the FME method provides a well-defined standard criterion for 
the evaluation ofresults. In addition, it provides a systematic approach to select 
concentration ratios that encompass a broad range coverage for combination 
studies. Thus, in turn, enables a complete understanding on the interaction 
profile exhibited by antimicrobial combinations. 
The success of our present studies in demonstrating the ability of the 
FME method to reproduce the synergistic interaction on PAE exhibited by the 
rifampin/tobramycin combination against E. coli ATCC 25922 provides 
supportive evidence for its validity for the investigation of PAE exhibited by 
antimicrobial combination. 
In addition, the FME method was further applied to study the PAE 
induced by the ciprofloxacin/tetracycline combination against E. coli ATCC 
25922 and the ciprofloxacin/gentamicin combination against Ps. aeruginosa 
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ATCC 27853. Through these studies, the ability of the FME method to 
determine antagonistic interaction on PAE exhibited by antimicrobial 
combinations was demonstrated. 
Studies on the above three test combinations demonstrated the ability of 
the FME method in determining both synergistic and antagonistic interactions 
on PAE. 
In addition, the FME method enables the determination of the highest 
interactive ratio for antimicrobial combinations. This is useful for the selection 
ofantimicrobial combination for chemotherapy. 
Previous studies on the PAEs induced by antimicrobial combinations 
were performed by subjecting the test organism to simultaneous exposure to the 
antimicrobial combination. All ofthese studies have not considered the common 
practice of sequential administration for antimicrobial combinations in 
chemotherapy, which is the result of the independent dosing schedules for 
individual antimicrobials. In view of this, our studies were designed to 
investigate the PAE exhibited by the antimicrobial combinations that are 
administered sequentially. 
A systematic approach based on the state of bacteria to standardize the 
selection of administration intervals for sequential administration studies was 
proposed and then applied in our studies. Compared to the arbitrary 
administration interval used by previous studies, our present approach for the 
standardization of administration intervals for sequential administration studies 
enables comparison of results between studies. 
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In our present studies, the postantibiotic phase was used as the basis to 
define the administration interval for the sequential administration studies on the 
PAE induced by the rifampin/tobramycin combination against E. coli ATCC 
25922. The test organism was subjected to one-hour of exposure to the first 
antibiotic. This was followed by another hour of exposure to the second 
antibiotic at the beginning, in the middle or at the end of the postantibiotic phase 
induced by the first antibiotic. 
As demonstrated by our studies, both the order and interval ofantibiotic 
exposure affect the overall PAE induced by the sequential administration of the 
rifampin/tobramycin combination against E. coli ATCC 25922. Whenever the 
sequential administration ofthis combination is adopted, these two aspects must 
be considered carefully. According to our observations, for the sequential 
administration of the rifampin/tobramycin combination against E. coli ATCC 
25922, it is recommended to initiate treatment with tobramycin followed by 
rifampin administered within the postantibiotic phase induced by tobramycin 
pre-exposure. Or with the reversed order of antimicrobial exposure, i.e., 
rifampin followed by tobramycin, the administration of rifampin is advised to be 
followed by tobramycin administering at the end of the PAE phase of rifampin. 
Only by the above stated administration schedules, can the additive PAE 
produced by the combination be ensured. The administration of rifampin 
followed by that of tobramycin within the postantibiotic phase induced by 
rifampin should be avoided. Otherwise antagonistic interaction on PAE would 
result. 
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The sequential administration of the rifampin/tobramycin combination 
against E. coli ATCC 25922 during the postantibiotic phase did not prolong the 
overall PAE induced by the combination. Such administration schedules 
produced additive or antagonistic PAE only. Therefore when one decides to 
extend the administration interval for this combination, the normal independent 
dosing schedules for individual antibiotics should be avoided in order to prevent 
the administration of antibiotics within the postantibiotic phase. Otherwise, 
antagonistic PAE produced by the combination may result. 
Antimicrobial resistance has been a critical issue concerning 
antimicrobial chemotherapy. Its effect on PAE induced by antimicrobial 
combinations and thus on the design of dosing regimen for antimicrobial 
combinations may impose significant impacts on the design of dosing regimens 
for antimicrobial combinations for combating resistant pathogens. Therefore， 
our present studies aims at studying the effect of antimicrobial resistance on the 
PAE induced by antimicrobial combinations. 
Previous studies have used clinical isolates for the investigation of PAE 
against resistant organisms. This seriously limits the determination of the effects 
of the type and extent of antimicrobial resistance on PAE produced by 
antimicrobial combinations. Therefore, in our present studies, a series of 
bacteria with increasing resistance to individual test antibiotic were used in 
order to allow detailed investigation on the effect of antimicrobial resistance 
including the effects of the type and extent of resistance on PAE produced by 
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antimicrobial combinations. The test bacteria were prepared by serial passages 
to two-fold increasing concentration of the test antibiotics 
With the study on the combination of piperacillin and gentamicin against 
Ps, aeruginosa, we demonstrated that piperacillin resistance in Ps. aeruginosa 
(0.5MIC, lMIC, and 2MIC) did not affect the PAE produced by the 
combination. On the contrary, gentamicin resistance in Ps. aeruginosa increased 
from 0.5MIC to 2MIC produced an abrupt decrease in the PAE induced by the 
combination from 1.79 to 0.42 h. Compared to the synergistic PAE induced by 
this combination against Ps. aemginosa ATCC 27853 (2.46 h), we showed that 
an increase in gentamicin resistance from 0.5MIC to 2MIC resulted in a 
significant decrease in the synergistic PAE produced by the combination. 
The observations ofour present studies provide important insight into the 
design of dosing regimen for the combination of piperacillin and gentamicin to 
combat Ps. aeruginosa with various degree of resistance to either piperacillin or 
gentamicin. Due to the presence of the synergistic PAE, gentamicin susceptible 
Ps. aeruginosa regardless of its piperacillin susceptibility may probably be 
treated with extended dosing of the combination of piperacillin and gentamicin 
without loss of efficacy. Whereas, because of a lack of significant PAE, 
gentamicin-resistant Ps. aeruginosa may require dosing schedules to maintain 
the antimicrobials serum and tissue level at or above their MIC throughout the 





Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour of 
exposure to a series of increasig concentration of rifampin 
Time (h) Control ~ Time (h) 16Mg/ml (1 M l c T " 
0 ^ 0 6.69 
1 6.32 1 5.66 
1.73 6.46 1.77 5.26 
2.37 6.71 3.15 4.88 
2.78 7.18 3.75 5.42 
3.25 7.60 4.5 5.97 
3.75 8.03 5.25 6.76 
. Time (h) 32jjg/ml(2^^fi3r"| Time (h) 64 Mfl/ml (4 MIC) 
0 K8^ 0 6.85 
1 5.92 1 6.59 
1.77 5.35 1.77 5.85 
3.15 丨 4.79 3.65 5.56 
3.75 4.94 4.5 5.39 
4.5 5.14 5.5 5.30 
5.25 5.46 6.5 6.09 
6 6.42 7.55 Z ^ 
7 1 _ ^ 
Time (h) 256 MQ/ml (16 MIC) Time(h) 128pg/ml(8MIC) 
0 ‘ ^ 0 6.85 
1 6.32 1 6.56 
1.77 5.75 1.77 5.79 
3 65 5.67 3.65 5.69 
4.5 5.59 4.5 5.60 
5.5 5.61 5.5 5.39 
6.5 5.50 6.5 5.65 
7.55 6.34 7.55 ^ 
7.95 6 ^ 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour of 
exposure to a series of increasing concentration of tobramycin 
Time (h) Control Time (h) 1 Mg/ml (0.5 MIC) 
0 5 m 0 5.77 
1 6.32 1 6.04 
1.73 6.46 1.78 5.80 
2.37 6.71 3 6.31 
2.78 7.18 3.5 6.56 
3.25 7.60 4 7.09 
3.75 8 ^ 4.5 L69 
Time (h) |1.5 Mg/ml (0.75 1 ^ ^ Time (h) 2 Mg/ml (1 MIC) 
0 ^ 0 6.76 
1 6.92 1 6.50 
1.77 6.33 1.78 5.41 
3.15 6.69 3 5.40 
3.75 6.93 3.53 5.48 
4.5 7.62 4 6.08 




Time (h) 3pg/ml(1.5MIC) Time (h) 6 Mmcg/ml (3 MIC) 
0 ^ 0 6.86 
1 5.33 1 1-79 
1.77 4.33 1.77 1.92 
3.1 4.24 3.15 2.15 
4 4.51 3.75 2.18 
4.95 5.15 4.5 2.38 
5 95 6.10 5.25 2.68 
7 7.34 ‘ 6 3.22 
Time (h) 8 Mg/ml (4 MIC) 







7.7 3 ^ 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to a series of increasing concentration oftetracycline 
Time(h)| Control |Time (h)| 1 pg/ml (0.5 M l c T " 
~ ~ 0 ^ 0 6.84 
1 6.16 1 6.83 
1.8 6.20 1.8 6.58 
2.85 7.08 3 7.16 
3.6 7.86 3.5 7.64 
4.15 ^ 4 8.13 
Time (h)| 2 gg/ml (1 MIC) |Time (h)| 4 Mg/ml (2 MIC) 
~ ~ 0 ^ 0 6.91 
1 5.97 1 5.41 
1.8 5.67 1.8 5.14 
2.95 6.07 3.05 5.74 
3.6 6.39 3.6 5.87 
4.15 6.86 4.15 6.02 
4.5 7.42 4.5 6.35 
5 ^ 7_^ 5.15 7.07 
“ 5.55 7.43 
6.15 ~JJ± 
Time (h)| 8 ^jg/ml (4 MIC) |Time (h)| 16 MQ/ml (8 W C ) ~ 
"""0 673 0 6.80 
1 5.06 1 5.34 
1.78 4.95 1.77 5.54 
3.5 5.67 3.5 5.67 
4 5.73 4 5.69 
4.5 5.95 4.5 5.98 
5.05 6.35 5.05 6.40 
5.5 6.93 5.5 6.92 
Time (h)| 32pg/ml(16MIC) |Time (h)| 48 gg/ml (24 MIC) 
•""^ 0 6：^ 0 6.83 
1 5.65 1 4.96 
1.75 5.60 1.8 4.30 
3.5 5.66 3.15 5.11 
4 5.76 3.6 5.15 
4.5 5.94 4.15 5.22 
5.05 6.35 4.5 5.28 






Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to a series of increasing concentration of ciprofloxacin 
Time (h C o _ l |Time (h| 0.0125 MQ/ml (0.5MIC) 
~ 0 ^ " " ^ 0 ~ ~ 6.76 
1 6.32 1 6.80 
1 73 6.46 1.72 6.62 
2.37 6.71 2.5 7.00 
2.78 7.18 3 7.53 
3.25 7.60 3.5 7.85 
3.75 8 ^ 4 8 ^ 
Time(h| 0.01875 MQ/ml (0.75 MIC) |Time (h 0.025 Mg/ml (1 MIC) 
~ ~ 0 e7ri ~ ~ o ~ ~ 6.67 
1 6.33 1 5.48 
1.73 5.98 1.73 4.94 
2 5 6.03 2.5 4.58 
3 6.58 3 4.81 
3 5 7.01 3.5 5.38 
4 7.44 4 5.91 
4.57 L5Z 4.63 ^ 
Time (h 0.0375 MQ/ml (1.5 MIC) |Time (h 0.05 Mg/ml (2 MIC) 
~ " 0 ^S2 0 6.86 
1 4.15 1 3.50 
1 72 3.73 1.73 3.20 
3 25 4.01 2.5 3.19 
3 75 4.47 3.05 3.19 
4 4.65 3.7 3.59 
4 53 5 ^ 4 4.01 
4.5 ^ 
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Data forthe regrowth kinetics of Ps. aeruginosa ATCC 27853 following 
one hour of exposure to a series of increasing concentration of 
gentamicin. 
Time (h Control ~ |Time (h 0.5 Mg/ml (1/8 M l c T 
~ ~ 0 ^ 0 6.27 
1 5.72 1 6.20 
1.75 5.66 1.73 5.77 
2.57 6.03 3 6.52 
3 6.45 3.5 7.06 
3.5 6.89 4.07 7.38 
3.93 7 ^ 
Time (h 1 Mg/ml (0.25MIC) |Time (h 2 pg/ml (0.5 MIC) 
~ 0 ^ ~ ~ 0 " " " 6.65 
1 4.55 1 3.17 
1 78 4.32 1.77 2.96 
3.08 4.47 3.53 2.93 
3.58 4.45 4.05 3.38 
4 23 4.70 4.73 3.76 
4 55 5.00 5.02 4.02 
5.05 5.31 5.65 4.52 
5.65 ^ 6 t Z 5 
Time (h 4 Mg/ml (1 MIC) |Time (h 6 Mg/ml (1.5 MlC) 
~ " 0 6 ^ 0 6.32 
1 3.07 1 2.20 
1.77 2.85 1.75 2.42 
3.22 2.78 3.53 2.57 
4 28 3.21 4.42 2.77 
4.68 3.18 5.88 3.09 
5.23 3.40 6.48 3.34 
5.82 3.85 6.97 3.55 
Time (h 8 Mg/ml (2 MIC) 







7.77 4 ^ 
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Data for the regrowth kinetics of Ps. aeruginosa ATCC 27853 following 
one hour of exposure to a series of increasing concentration of 
ciprofloxacin. 
Time (h Control |Time (h 1 ug/ml (1 MIC) 
~ 0 ^ ~ ~ 0 ~ ~ 6.41 
1 5.72 1 5.23 
1.75 5.66 1.72 4.86 
2.57 6.03 3 5.11 
3 6.45 3.75 5.27 
3.5 6.89 4.5 5.85 
3.93 1 ^ 5.08 ^ 
Time(h| 1 .5m/ml (1 .5MIC) |Time (h 2 卯 /ml (2 M I Q ~ 
~ ~ 0 ^ 0 6.50 
1 4.83 1 3.77 
1.78 4.42 1.73 3.46 
3 75 4.74 3.5 3.55 
4:25 5.01 4.42 3.88 
4 75 5.14 5.02 4.27 
5.35 5.56 5.82 4.58 
5.85 ^ 6.38 ^ 
Time (h 4 pg/ml (4 MIC) |Time (h 6 MQ/ml (6 MIC) 
~ ~ 0 ^ 0 6.41 
1 2.69 1 1-70 
1.73 2.35 1.72 1.79 
4 2.65 4 2.18 
5.02 2.85 5 2.35 
5.82 3.03 5.75 2.39 
6.57 3.39 6.5 2.73 





Data for the concentration response curve for rifampin against 
E. coli ATCC 25922 
fRifampinl Oig/ml) |PAE (h)_ 
0 0.00 
16 1.64 
32 2.81 PAE^ax 4.78 
64 3.99 EC50 24.65 
128 4.33 n 1.55 
^ 4.70 
Data forthe concentration response curve fortobramycin against 
E. coli ATCC 25922 
Tfobramycin] (Mg/ml) |PAE (h) 
1 0.58 
1.5 1.05 
2 1.67 PAEmax 2.63 
3 2.01 EC50 1.709 
6 2.45 n 2.345 
8 2.62 
Data for the concentration response curve for ciprofloxacin against 
E. coli ATCC 25922 
IcIprofloxacin] (pg/ml)|PAE (hj 
0 0 
0.0125 0.06 
0.01875 0.37 PAEmax 1-05 
0.025 0.89 EC50 0.02 
0.0375 0.99 n 7.553 
0.05 1.09 
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Data forthe concentration response curve fortetracycline against 
E. coli ATCC 25922 





8 1.56 PAEmax 3.41 
16 2.24 ECso 8.01 
32 2.53 n 0.78 
^ 1.57 
Data for the concentration response curve for ciprofloxacin agains 
Ps. aeruginosa ATCC 27853 
TcTprofloxacin] (pg/ml)| PAE (h) 
1 T^^~~ 
1.5 1.88 PAEmax 3.89 
2 2.28 ECso 1.56 
4 3.26 n 1.59 
6 3.44 
Data forthe concentration response curve for gentamicin against 
Ps. aeruginosa ATCC 27853 
"lGentamicin] (|jg/ml) PAE (h) 
o l o31 ~ ~ 
1 1.79 
2 1.69 PAEmax 4.28 
4 2.54 EC50 2.42 







Data forthe regrowth kinetics of E. coli ATCC 25922 following one 
hour of exposure to five different combinations of rifampin and 
tobramycin. 
Time (h)| Control ~ Time (h) 0.2 FME of Rif &~~ 
0 5 ^ 0.8 FME of Tobra 
1 6:32 ~ ~ 0 ^ 
1.73 6.46 1 3.06 
2.37 6.71 1.78 3.35 
2.78 7.18 3.3 3.22 
3 25 7.60 5.55 3.19 
3.75 8.03 6.6 3.33 
“ 7.5 4.12 
8.55 ^ 
Time(h)| 0 . 4 F M E o f R i f & |Time (h)| 0.5 FME ofRi f&~~ 
0.6 FMEof Tobra 0.5FMEofTobra 
" " " 0 ^ ~ ~ 0 ~ " 6.98 
1 3.93 1 5.82 
1.78 3.46 1.78 5.42 
3.85 3.60 3.3 4.81 
4 8 3.48 5.35 3.55 
5 8 3.40 6.6 3.79 
6.8 3.77 7.5 4.78 
7 8 4.81 8.55 5.75 
8.8 5.80 9.15 6.47 
9.75 6 ^ 
Time(h)| 0 . 6FMEofR i f& |Time(h)| 0 . 8 F M E o f R i f & 
0.4 FME of Tobra 0.2 FME of Tobra 
0 ^ 0 ~ ~ 6.85 
1 5.98 1 6.08 
1.78 5.59 1.78 5.69 
3 3 4.97 3.3 5.50 
5.35 4.35 5.35 4.81 
6.6 5.10 6.6 5.20 
7.5 6.17 7.5 6.27 
8.55 7.22 8.55 7.41 
9.15 7.74 9.15 7.86 
Rif: Rifampin 
Tobra : Tobramycin 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one 
hour of exposure to five different combinations of tetracycline and 
ciprofloxacin. 
Time (h)| Control |Time(h)| 0 .2FMEofTe t ra& 
0 5；^ 0.8 FME of Cipro 
1 6.16 ~ 0 ^ 
1:8 6.20 1 6.17 
2.85 7.08 1.78 5.63 
3.6 7.86 3.5 6.15 
4.15 S M 4 6.53 
“ ~ ~ 4.5 6.97 
5 7 ^ 
Time (h)| 0.4 FME ofTetra & |Time(h)| 0 .5FMEofTet ra& 
0.6 FMEofCipro 0.5 FMEofCipro 
~~"0 ^ " " " 0 ~ " 6.95 
1 5.51 1 5.18 
1.77 5.12 1.77 4.67 
3.55 5.82 3.5 5.48 
4 5.90 4 5.59 
4.5 6.07 4.5 5.81 
5 6.60 5 6.21 
5.65 1.22 5.5 6.89 
‘ 6.1 7.60 
Time (h)| 0.6 FMEofTetra& Time (h) 0 .8FMEofTet ra& 
0.4 FME of Cipro 0.2 FME of Cipro 
~ ~ 0 ^ ~ ~ 0 ^ 
1 5.06 1 5.56 
1 77 4.49 1.77 5.13 
3.5 5.12 3.3 5.37 
4.5 5.33 4.2 5.36 
5.5 6.22 5.15 5.90 
6.5 7.25 I 6.3 6.67 
Tetra : Tetracycline 
Cipro : Ciprofloxacin 
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Data forthe regrowth kinetics of Ps. aeruginosa ATCC 27853 
following one hour of exposure to five different combinations of 
ciprofloxacin and gentamicin 
Time (h)| Control ~ " |Time (h)| 0.2 FMEofCipro 
0 ^ & 0.8 FME ofGen 
1 5.72 " " " 0 ^ 
1.75 5.66 1 1-93 
2.57 6.03 1.72 2.09 
3 6.45 5.75 2.79 
3 5 6.89 6.52 3.17 
3.93 7.38 7.43 3.75 
Time (h)| 0.4 FME ofCipro |Time (h)| 0.5 FMEofCipro 
& 0.6 FME ofGen & 0.5 FME ofGen 
0 6 l ^ 0 6.59 
1 2.89 1 2.48 
1.77 2.13 1.73 2.00 
4 2.24 4 1.98 
4.9 , 2.40 4.92 2.45 
5.57 2.71 5.58 2.70 
6.25 3.07 6.27 3.24 
7 ^ 7 ^ 
Time (h)| 0.6 FMEofCipro |Time (h)| 0.8 FME ofCipro 
&0.4 FME ofGen & 0.2 FME ofGen 
~ ~ 0 6：47 ~ ~ 0 ~ ~ 6.50 
1 2.94 1 1-18 
1.77 2.68 1.75 1.54 
4.07 2.70 4.08 1.24 
4.82 2.92 4.85 1.48 
5.63 3.42 5.55 1.98 
6.72 3.79 6.73 2.45 
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121 _.. * 
9 j ~ " " 
；：^^^ 
t> ~ • — Control 
^ 4 - - —A— 1.71 pg/ml Tobramycin (0.5 ME) 
2 • 1.71 pg/ml Tobramycin (0.5 ME) 
—m—^.7^ pg/ml Tobramycin (0.5 ME) 
2 一 —A—24.65 pg/ml Rifampin (0.5 ME) 
1 - ) f - 2 4 . 6 5 pg/ml Rifampin (0.5 ME) 
X 24.65 pg/ml Rifampin (0.5 ME) 
0 i i 1 丨 I ‘ ‘ ~ 
0 1 2 3 4 5 6 7 8 
Time (hour) 
Growth kinetics of E. coli following one hour of exposure to 
eithertobramycin or rifampin 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 1.71 pg/ml tobramycin 
Time (h) Control Time (h) Tobramycin 
0 5 ^ 0 6.71 
1 6.03 1 6.13 
1.77 6.13 1.77 5.53 
2.62 6.85 3.25 5.60 





Time (h) Tobramycin Time (h) Tobramycin 
0 ^ 0 6.95 
1 6.51 1 7.01 
1.77 5.87 1.77 6.45 
3.25 6.38 3.3 6.85 
3.75 6.46 3.75 7.12 
4.25 6.79 4.25 7.42 
4.75 7.22 4.75 7.82 
5.25 7.60 5.3 8.10 
5.75 8.00 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 24.65 ^Jg/ml rifampin 
Time (h) Control Time(h) Rifampin 
0 ^ 0 6.82 
1 6.03 1 5.60 
1.77 6.13 1.77 5.38 
2.62 6.85 3.3 5.14 





Time (h) Rifampin Time(h) Rifampin 
0 ^ 0 6.74 
1 5.23 1 5.16 
1 77 5.21 1.77 5.25 
3.3 4.78 3.25 4.91 
4.25 5.16 4.25 5.03 
5.3 5.68 5.3 5.61 
5.8 6.15 5.75 6.12 
6.25 6.97 6.25 6.85 
6.8 7.23 6.75 7.33 
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9 1 — “ 
,?w5-：^  
g 5 - - ^ = ^ ^ ^ ^ » C ^ ^ y^A^=H^Control 
^4 ^ « ^ f e ： ^ ^ ^ 
_i ^"-Ef*- —0—24.65 [jg/ml Rifampin 
(0.5 ME)+ 1.71 Mg/ml 
3 -- Tobramycin ( 0.5 ME ) 
A 24.65 pg/ml Rifampin 
2 .. (0.5 ME)+ 1.71 Mg/ml 
Tobramycin ( 0.5 ME) 
X 24.65 |jg/ml Rifampin 
1 -- (0.5 ME)+ 1.71 Mg/ml 
Tobramycin ( 0.5 ME ) 
0 \ 1 1 1 1 ‘— 
0 2 4 6 8 10 12 
Time (hour) 
Growth kinetics of E. coli following one hour of exposure to 
the combination of rifampin & tobramycin. 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 1.71 ^ig/ml tobramycin & 24.65 pg/ml rifampin 
Time (h) Control Time (h) Tobramycin 
0 5^8 & Rifampin 
1 6.18 0 6.82 
1.78 3.42 1 4.98 
2 78 4.02 1-77 4.86 
3 25 4.62 3.25 4.05 
4 25 5.57 4.25 3.69 
5.4 6.74 5.4 3.84 
5 84 7.23 6.25 4.38 
5.87 5.34 7.25 5.30 
6.87 5.96 8 6.05 
7.64 6.11 8.75 6.85 
8 62 6.82 9.25 7.44 
9.12 7.36 10-25 8.05 
10.12 8.10 
Time (h) Tobramycin""" Time(h) Tobramycin 
& Rifampin & Rifampin 
0 ^ 0 6.96 
1 5.26 1 4.89 
1 75 5.44 1.78 4.89 
3 25 4.77 3.3 4.10 
4 4 3.85 4.25 4.01 
5 3 4.04 5.25 3.86 
6 25 4.36 6.25 3.99 
7 25 5.41 7.25 4.98 
8 3 6.46 8.25 6.01 
9.3 7.43 9.25 6.91 
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9 1 
I � ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ � � — 
o 
cn 4 --
_3 —m— 1 st 24.65 pg/ml Rifampin & 
2nd 1.71 pg/ml Tobramycin 
3 - - addition after centrifugation 
A 1 st 24.65 ng/ml Rifampin & 
2 . _ 2nd 1.71 ng/ml Tobramycin 
addition after centrifugation 
X 1 st 24.65 pg/ml Rifampin & 
1 - - 2nd 1.71 ^jg/ml Tobramycin 
addition after centrifugation 
oJ 1 H— ‘ ‘ ‘ 
0 2 4 6 8 10 12 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to rifampin 
and then 2nd exposure to tobramycin just after 1st drug 
removal 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 24.65 pg/ml rifampin followed by one hour of exposure 
to 1.71 pg/ml tobramycin at the beginning ofthe postantibiotic phase 
produced by rifampin pre-exposure 
Time (h) Control Time (h) Rif & Tobra 
0 5 ^ 0 ^ 
1 6.26 1 5.63 
1.85 5.18 1.8 5.64 
2.85 5.85 2.8 5.04 
3.7 5.99 3.58 4.79 
4.73 6.79 5.32 4.62 
5.1 7.26 6.05 4 .69 
5.65 7.79 6.55 4.86 
6.1 8.06 7.1 5.11 





Time (h) Rif & Tobra Time (h) Rif & Tobra 
0 6 ^ 0 6.85 
1 5.81 1 5.94 
1.8 5.54 1.8 5.97 
2.8 5.02 2.8 5.16 
3.58 4.66 3.6 4.71 
5.05 4.76 5.05 4.60 
6.05 4.80 6.05 5.00 
7.05 5.44 7.05 5.64 
8.05 6.61 8.05 6.74 








• 1 st-24.65 ^jg/ml Rifampin & 2nd-1.71 pg/ml 
2 Tobramycin addition at mid-PAE phase 
—m— 1 st-24.65 pg/ml Rifampin & 2nd-1.71 ^jg/ml 
Tobramycin addition at mid-PAE phase 
1 “ - ~~ts~~ 1 st-24.65 pg/ml Rifampin & 2nd-1.71 \^ g/m\ 
Tobramycin addition at mid-PAE phase 
0 1 1 i 1 1 
0 2 4 6 8 10 12 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to rifampin 
and then 2nd exposure to tobramycin at the mid-PAE-phase 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 24.65 pg/ml rifampin followed by one hour of exposure 
to 1.71 pg/ml tobramycin in the middle ofthe postantibiotic phase 
produced by rifampin pre-exposure 
Time (h) Control Time (h) Rif & Tobra 
0 ^ 0 6.73 
1 6.11 1 5.59 
1.78 6.00 1.78 5.52 
2.75 6.74 3.25 4.42 
3.25 7.39 3.81 4.51 
3.81 5.64 4.81 3.84 
4.81 6.13 5.63 3.64 
5.68 5.82 7.06 3.87 
6.56 6.53 8.06 4.38 
7.06 7.18 9.06 5.38 
8.06 ^ 10.06 6.37 
Time (h) Rif & Tobra Time (h) Rif & Tobra 
0 6 ^ 0 6.65 
1 5.67 1 5.63 
1.77 5.41 1.77 5.76 
3.5 4.91 3.25 5.22 
3.87 4.71 3.83 4.82 
4.87 4.11 4.83 4.03 
5.65 3.94 5.58 3.94 
7.12 4.41 7.13 4.15 
8.12 4.93 8.08 4.68 






-^ •—Conti^  
2 .. A 1 st-24.65 pg/ml Rifampin & 
2nd-1.71 pg/ml Tobramycin 
X 1 st-24.65 pg/ml Rifampin & 
1 -- 2nd-1.71 ^jg/mlTobramycin 
~I~"1st-24.65 pg/ml Rifampin & 
2nd-1.71 pg/ml Tobramycin 
0 1 1 i i ~ ~ I ~ — ^ = ^ = ^ ^ = ^ ^ ^ ^ 
0 2 4 6 8 10 12 14 16 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to rifampin and 
then 2nd exposure to tobramycin at the end ofthe PAE-phase 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 24.65 pg/ml rifampin followed by one hour of exposure 
to 1.71 pg/ml tobramycin at the end of the postantibiotic phase 
produced by rifampin pre-exposure 
Time (h) Control Time (h) Rif & Tobra 
0 ^ 0 6.75 
1 6.18 1 5.60 
1.78 3.42 1.78 5.42 
2.78 4.02 3.55 4.75 
3.25 4.62 4.25 5.04 
4.25 5.57 5.38 5.56 
5.4 6.74 5.9 6.23 
5.84 7.23 6.9 3.21 
5.87 5.34 7.68 2.94 
6.87 5.96 9.15 3.32 
7.64 6.11 10.15 3.56 
8.62 6.82 11.15 4.52 
9.12 1 ^ 11-65 1：95 
Time (h) Rif & Tobra Time (h) Rif & Tobra 
0 e m 0 6.95 
1 5.78 1 5.51 
I.75 5.74 1.83 5.73 
4 5.02 4.35 5.41 
5 5.19 5.25 5.61 
5.83 6.05 5.92 6.10 
6.83 3.31 6.92 3.69 
7.63 3.09 7.67 3.06 
9.23 3.67 9.17 3.22 
10.08 4.00 — 10.17 3.51 






r k ^ 
• Control 
3 --
~ S ~ 1 st 1.71 pg/ml Tobramycin & 2nd 24.65 
pg/ml Rifampin addition after centrifugation 
—A— 1 st 1.71 [jg/ml Tobramycin & 2nd 24.65 
pg/ml Rifampin addition after centrifugation 
1 - ‘ ~ X ~ 1 st 1.71 pg/ml Tobramycin & 2nd 24.65 
pg/ml Rifampin addition after centrifugation 
0 1 i 1 1 ^ 
0 2 4 6 8 10 12 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to 
tobramycin and then 2nd exposure to rifampin just after 1st 
drug removal 
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Data forthe regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 1.71 ^ig/ml tobramycin followed by one hour of exposure 
to 24.65 pg/ml rifampin at the beginning ofthe postantibiotic phase 
produced by tobramycin pre-exposure 
Time (h) Control Time (h) Tobra & Rif 
0 ^ 0 6.86 
1 6.26 1 7.05 
1.85 5.18 1.85 6.03 
2.85 5.85 2.85 4.48 
3.7 5.99 3.65 4.77 
4.73 6.79 5.33 4.00 
5.1 7.26 6.1 4.06 
5.65 7.79 7.15 4.06 





Time (h) Tobra & Rif Time (h) Tobra & Rif 
0 6：^ 0 6.72 
1 6.89 1 7.12 
1.85 6.01 1.8 6.52 
2.85 4.83 2.8 4.90 
3.63 4.58 3.6 5.03 
5.1 4.05 5.05 4.59 
6.1 4.01 6.05 4.26 
7.1 3.98 7.05 4.74 
8.1 4.29 8.05 5.13 
9.1 5.07 9.05 5.94 




9 1 — 
.F<y 
」 - ) < - C o n t r o l 
3 --
• 1 st-1.71 pg/ml Tobramycin & 2nd-24.65 
pg/ml Rifampin addition at mid-PAE phase 
2 --
" i 3 “ 1 st-1.71 pg/ml Tobramycin & 2nd-24.65 
|jg/ml Rifampin addition at mid-PAE phase 
1 --
A 1 st-1.71 ^ig/ml Tobramycin & 2nd-24.65 
pg/ml Rifampin addition at mid-PAE phase 
0 1 ^ I I ‘ ‘ 
0 2 4 6 8 10 12 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to tobramycin 
and then 2nd exposure to rifampin at the mid-PAE-phase 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 1.71 jjg/ml tobramycin followed by one hour of exposure 
to 24.65 ^ig/ml rifampin in the middle of the postantibiotic phase 
produced by tobramycin pre-exposure 
Time (h) Control Time (h) Tobra & Rif 
0 ^ 0 6.64 
1 5.99 1 6.87 
1.78 5.95 1.78 6.59 
3.08 5.59 3.08 6.83 
4.08 6.23 4.08 5.29 
4.93 6.36 4.88 4.79 
5.9 7.00 6.38 4.10 




11.33 7 ^ 
Time (h) Tobra & Rif Time (h) Tobra & Rif 
0 ^ 0 6.85 
1 7.00 1 7.18 
I.77 6.47 1.75 6.77 
3.13 6.85 3.12 7.12 
4.13 5.26 4.12 5.24 
4.91 5.58 4.9 4.99 
6.25 3.99 6.42 4.08 
7.25 4.13 7.37 4.59 
8.38 4.45 8.37 4.86 
9.38 5.16 9.37 5.80 
10.38 6.41 10.37 6.87 




9 1 • i^ ^/^ 
o 
o) 4 .. ~•~~Control o ^ _j 
3 - - ~E1~ 1 st-1.71 pg/ml Tobramycin & 
2nd-24.65 pg/ml Rifampin 
2 - - A 1 st-1.71 pg/ml Tobramycin & 
2nd-24.65 ^jg/ml Rifampin 
1 “ "*"1st-1.71pg/mlTobramycin& 
2nd-24.65 pg/ml Rifampin 
0 1 1 H I = f = — = I 
0 2 4 6 8 10 12 14 
Time (hour) 
Growth kinetics of E. coli following 1st exposure to 
tobramycin and then 2nd exposure to rifampin at the end of 
the PAE-phase 
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Data for the regrowth kinetics of E. coli ATCC 25922 following one hour 
of exposure to 1.71 jjg/ml tobramycin followed by one hour of exposure 
to 24.65 [jg/ml rifampin at the end of the postantibiotic phase produced 
by tobramycin pre-exposure 
Time (h) Control Time (h) Tobra & Rif 
0 5 ^ 0 6.54 
1 5.96 1 6.06 
1.8 5.11 1.77 5.49 
2.75 5.77 3.25 5.65 
3.25 6.36 3.88 5.85 
3.78 6.92 4.36 5.98 
4.32 7.38 4.42 6.16 
4.33 5.49 5.42 4.60 
5.33 6.07 6.19 5.05 
6.1 6.04 7.74 4.62 
7.08 6.93 8.75 4.71 
7.61 7.52 9.67 5.52 
8.08 7.96 10.42 6.39 
Time (h) Tobra & Rif Time (h) Tobra & Rif 
0 ^ 0 6.84 
1 6.88 1 7.01 
I .77 6.20 1.75 6.51 
3.3 6.94 3.25 7.01 
4.43 7.33 4.42 7.69 
5.43 5.98 5.42 6.92 
6.2 6.11 6.17 6.69 
7.68 6.05 7.72 6.49 
8.68 6.19 8.67 6.12 
9.68 6.74 9.72 6.85 
10.68 7.33 10.67 7.55 








8.00 -- • • jc i -" -^^ 
7.00 -- y^gj<^^^"^""®""""""""""^ 
. :^¾^ 
」 " 棚 - . ^ ^ ^ ^ ^ ^ ^ ^ ^ _ _ _ _ _ ^ ^ ^ ^ ^ ^ I 
3.00 - ^ ^con t ro l 
~ i l ~ 3 2 pg/ml piperacillin 
2 . 0 0 --
A 1 ^ig/ml gentamicin 
1 . 0 0 - -
X 32 ^ig/ml piperacillin & 1 
pg/ml gentamicin 
0.00 i i ^ I ‘ ‘ 
0 1 2 3 4 5 6 7 
Time (hour) 
Growth kinetics of Ps. aeruginosa ATCC 27853 following 
one hour of exposure to piperacillin, gentamicin and their 
combination 
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Data for the regrowth kinetics of Ps. aeruginosa ATCC 27853 
following one hour of exposure to piperacillin, gentamicin and their 
combination 
Time (h) Control Time (h) |32 pg/ml piperacillin 
0 0 ^ 0 6.51 
1 6.50 1 6.38 
2 6.40 2 5.40 
2.75 7.49 2.75 6.67 
3.5 7.61 3.5 7.04 
4.25 7.61 4.25 7.30 
5 i m 5 7.57 
5.75 7.88 
Time (h) 1 pg/ml gentamicin Time (h) |32 ^ig/ml piperacillin 
0 6.53 1 MQ/ml gentamicin 
1 5.09 0 ^ 
2 4.48 1 4.14 
2.75 4.60 2 3.34 
3.5 4.95 2.75 3.29 
4.25 5.71 3.5 3.40 






7 � � , ^ ^ ^ = = ^ ^ ^ ^ ^ ^ _ ^ / < l ^ ^ ^ ^ ^ " " ^ ^ " “ ^ ‘ 
- " ^ = ^ ^ = = = = : : : q ^ ： ： ： ： ： ^ ^ ^ ^ 
! 5 � ^ ^ ^ _ ^ ^八 ^ > ^ ^ ^ ^ " ^ " " ^ 
•§ 4.00 -- ^ ^ ""•~"Control 
0) o _j 
3.00 -- -H1~32 pg/ml piperacillin 
2.00 -- A 1 pg/mlgentamicin 
1 -00 - - —>f— 32 pg/ml piperacillin & 
1 ^jg/ml gentamicin 
0.00 1 I 1 1 ‘ 
0 1 2 3 4 5 6 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant strain 
(resistant to 1 ^jg/ml of gentamicin) following one hour of 
exposure to piperacillin, gentamicin and their combination 
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Data for the regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 1 pg/ml of gentamicin) following one hour of exposure to 
piper3cillin, gentamicin ortheir combination 
Time (h) Control Time (h) 32 MQ/ml piperacillin 
0 6 ^ 0 6.50 
1 6.61 1 6.20 
2 6.21 2 5.78 
2.75 7.31 2.75 6.43 
3.5 7 ^ 3.5 7.06 
4.25 7 ^ 
Time (h) 1 pg/ml gentamicin Time (h) 32 Mg/ml piperacillin & 
0 6.53 1 pg/ml gentamicin 
1 6.18 0 6 ^ 
2 5.74 1 4.98 
2.75 5.86 2 4.13 
3.5 6.70 2.75 4.30 
4.25 7.31 3.5 4.53 





8.00 -• __^ 
7.00 -- _ _ ^ ^ _ _ _ _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ = " " ^ 
6.00 丨卜‘‘“ ~^--"^ ~§"^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ 1^11：^^ ^^ "^"""^ !^!^ ^^ ^^ ^^ ^^ ^^ "^  
c r" «« — • “ “ Control 
I 5.00 --
t3 
o 4.00-- —®—32 pg/ml piperacillin 
3.00 --
A 1 ^jg/ml gentamicin 
2 . 0 0 - -
X 32 pg/ml piperacillin & 
1 •〇〇-- 1 pg/ml gentamicin 
0.00 J 1 1 1 ‘ 
0 1 2 3 4 5 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant strain 
(resistant to 2 ^ig/ml of gentamicin) following one hour of 
exposure to piperacillin, gentamicin and their combination 
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Data forthe regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 2 pg/ml of gentamicin) following one hour of exposure 
to piperacillin, gentamicin ortheir combination 
Time (h) Control Time (h) 32 Mg/ml piperacillin 
0 6 ^ 0 6 M 
1 6.51 1 6.27 
2 6.19 2 5.93 
2.75 7.22 2.75 6.35 
3.5 7.69 3.5 6.92 
4.25 l _ ^ 
Time (h) 1 M9/ml gentamicin| Time (h) 32 MQ/ml piperacillin & 
0 6.38 1 Mg/ml gentamicin 
1 6.51 0 ‘ ~ ~ ^ 
2 6.43 1 6.01 
2.75 7.00 2 5.83 
3.5 7.58 2.75 5.82 





7.00 -- ^ ^ : = = ' ' ' " " " ^ ] ^ ^ ^ " ^ - * 
e.oo ' " ^ ^ = = = ^ ^ ^ ^ ： ^ 
5.00 -- • Control 
^ 2 
S) 4.00 -- - f i h - 3 2 pg/ml piperacillin 
•3 
3.00 --
A 1 pg/ml gentamicin 
2 . 0 0 - -
X 32 ng/ml piperadllin & 
1-00 ‘“ 1 pg/mlgentamicin 
0.00 i 1 i i 1 1 1 ‘ 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant strain (resistant 
to 4 pg/ml of gentamicin) following one hour exposure to 
piperacillin, gentamicin and their combination 
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Data for the regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 4 pg/ml of gentamicin) following one hour of exposure 
to piperacillin, gentamicin ortheir combination 
Time (h) Control Time (h) 32 pg/ml piperacillin 
0 6 ^ 0 6.40 
1 6.51 1 5.99 
2 5.91 2 5.60 
2.75 6.88 2.75 5.99 
3.5 7.35 3.5 6.78 
4.25 7.49 4.25 7 ^ 
Time (h) 1 pg/ml gentamicin Time (h) |32 Mg/ml piperacillin & 
0 6 ^ 1 jjg/ml gentamicin 
1 6.45 0 6 M 
2 5.42 1 5.97 
2.75 6.76 2 5.30 
3.5 7.41 2.75 5.63 
4.25 7.44 3.5 6.70 
4.25 7 ^ 
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8.00 "j — — 
7 : ^ ^ c : ^ " ^ X ^ ::^ 1^_^  
•§ 4.00-- V ^ ^ ^ " ^ _ ^ , . , . - ^ " " " " ^ 
§> ^ X > < ' 7 ^ 
」 - # - C o n t r o l 
3.00 --
~Ea~ 32 ng/ml piperacillin 
2 . 0 0 - -
A 1 pg/ml gentamicin 
1 0 0 - -
X 32 pg/ml piperacillin 
& 1 pg/ml gentamicin 
0.00 i 1 1 I ‘ 
0 1 2 3 4 5 6 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant strain 
(resistant to 16 Mg/ml of piperacillin) following one hour of 
exposure to piperacillin, gentamicin and their combination 
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Data for the regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 16 pg/ml of piperacillin) following one hour of exposure to 
piperacillin, gentamicin ortheir combination 
Time (h) Control |Time (h)| 32 MQ/ml piperacillin 
0 6J5 0 e ^ 
1 6.53 1 5.93 
2 5.91 2 5.28 
2.75 7.23 2.75 6.77 
3.5 7 ^ 3.5 6 ^ 
Time (h) 1 _ m l gentamicin |Time (h)|32 pg/ml piperacillin & 
0 6.36 1 ^jg/ml gentamicin 
1 4.64 0 6 ^ 6 
2 4.11 1 3.98 
2.75 4.22 2 3.50 
3.5 4.31 2.75 3.54 
4.25 4.69 3.5 3.62 
5 5.10 4.25 3.93 
5.75 5.62 5 4.47 
5.75 5 ^ 
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8.00 1 
7.00 -- / ^ r " ^ ^ 
,:^L^ <^^  
I 4.00 -- \ ^<^" - "“^^ r " "^ ^^^.x-^"^^ 
� • - - ^ ""><^^"""^"[^ ^Control 
-H1~32 pg/ml piperacillin 
2 . 0 0 --
~ ^ k ~ 1 pg/ml gentamicin 
1 0 0 --
X 32 pg/ml piperacillin & 
1 tjg/ml gentamicin 
0.00 i 1 i 1 I ‘ 
0 1 2 3 4 5 6 7 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant strain 
(resistant to 32 pg/ml of piperacillin) following one hour of 
exposure to piperacillin, gentamicin and their combination 
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Data forthe regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 32 pg/ml of piperacillin) following one hour of exposure to 
piperacillin, gentamicin ortheircombination 
Time (h) Control Time (h) 32 MQ/ml piperacillin 
0 6 ^ 0 6 M 
1 6.45 1 5.74 
2 5.95 2 5.50 
2.75 7.32 2.75 6.95 
3.5 ^ 3.5 7 ^ 
Time (h) 1 pg/ml gentamicin Time (h) |32 pg/ml piperacillin & 
0 6.50 1 pg/ml gentamicin 
1 4.78 0 ^ 
2 4.35 1 3.78 
2.75 4.51 2 3.37 
3.5 4.64 2.75 3.42 
4.25 4.87 3.5 3.65 
5 5.46 4.25 3.86 
5.75 5 ^ 5 4.36 
5.75 ^ 
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8.00 1 — 
7.00 - y ^ m ^ ^ ^ ^ ^ ^ 
6 。 。 ^ ^ ^ = = ^ 
广 . V ^ _ _ ^ - ^ 
I 描 • • v ^ ^ ^ — — ^ " " " " " ^ ^ t ^ S : r : : l ! ^ 
3.00 -- ^ H "^ “^ ^ p i - C o n ^ 
~ M ~ 3 2 pg/ml piperacillin 
2 . 0 0 - -
A 1 ^jg/ml gentamicin 
1.00 - - —><— 32 pg/ml piperacillin & 
1 pg/ml gentamicin 
0.00 i 1 1 1 1 
0 1 2 3 4 5 6 
Time (hour) 
Growth kinetics of Ps. aeruginosa resistant starin 
(resistant to 64 pg/ml of piperaciilin) following one hour of 
exposure to piperacillin, gentamicin and their combination 
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Data forthe regrowth kinetics of Ps. aeruginosa resistant strain 
(resistant to 64 ijg/ml of piperacillin) following one hour of exposure to 
piperacillin, gentamicin ortheircombination 
Time (h) Control Time (h) 32 Mg/ml piperacillin 
0 6 ^ 0 ^ 
1 6.49 1 6.01 
2 5.82 2 5.28 
2.75 7.19 2.75 6.82 
3.5 l M 3.5 7 ^ 
Time (h) 1 pg/ml gentamicin Time (h) 32 ^jg/ml piperacillin & 
0 6.37 1 Mg/ml gentamicin 
1 4.46 0 ^ 
2 3.86 1 3.54 
2.75 3.93 2 3.03 
3.5 4.05 2.75 3.01 
4.25 4.29 3.5 3.17 
5 4.76 4.25 3.51 
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